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Regulation of Serum Albumin Production by Insulin
Abstract
Diabetes is accompanied by dysregulation of glucose, lipid, and protein metabolism. In recent years, much
effort has been spent on understanding how insulin regulates glucose and lipid metabolism, while the effect of
insulin on protein metabolism has received less attention. In diabetes, hepatic production of serum albumin
decreases, and it has long been established that insulin positively controls albumin gene expression. Yet, the
detailed pathway via which insulin exerts this effect has not been described. In this study, we used a genetic
approach in mice to identify the mechanism by which insulin regulates albumin production, both
transcriptionally and post-transcriptionally. Albumin expression was significantly decreased in livers with
insulin signaling disrupted by ablation of insulin receptor or Akt. Concomitant deletion of Forkhead Box O1
(Foxo1) in these livers rescued the decreased albumin secretion. Furthermore, expressing a constitutively
active Foxo1 in the liver is sufficient to suppress albumin expression. Mammalian Target of Rapamacin
Complex 1 (mTORC1) activity had a minor contribution to serum albumin production. Hepatic autophagy
also played a minor role and contributed to albumin production post-transcriptionally in the absence of
insulin signaling. In addition, we show that constitutive activation of Foxo1 is correlated with decreased
occupancy of CCAAT/Enhancer Binding Protein α (C/EBPα) at the albumin promoter. These results
demonstrate that serum albumin production is regulated mainly on the transcription level, and insulin
stimulates albumin expression by inhibiting Foxo1, which acts as a gene repressor of albumin by directly or
indirectly interfering with C/EBPα binding to the albumin promoter.
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ABSTRACT 
 
REGULATION OF SERUM ALBUMIN PRODUCTION BY INSULIN 
Qing Chen 
Morris J. Birnbaum, M.D., Ph.D. 
 
Diabetes is accompanied by dysregulation of glucose, lipid, and protein 
metabolism.  In recent years, much effort has been spent on understanding how 
insulin regulates glucose and lipid metabolism, while the effect of insulin on 
protein metabolism has received less attention.  In diabetes, hepatic production 
of serum albumin decreases, and it has long been established that insulin 
positively controls albumin gene expression.  Yet, the detailed pathway via which 
insulin exerts this effect has not been described.  In this study, we used a genetic 
approach in mice to identify the mechanism by which insulin regulates albumin 
production, both transcriptionally and post-transcriptionally.  Albumin expression 
was significantly decreased in livers with insulin signaling disrupted by ablation of 
insulin receptor or Akt.  Concomitant deletion of Forkhead Box O1 (Foxo1) in 
these livers rescued the decreased albumin secretion.  Furthermore, expressing 
a constitutively active Foxo1 in the liver is sufficient to suppress albumin 
expression.  Mammalian Target of Rapamacin Complex 1 (mTORC1) activity had 
a minor contribution to serum albumin production.  Hepatic autophagy also 
played a minor role and contributed to albumin production post-transcriptionally 
v 
in the absence of insulin signaling.  In addition, we show that constitutive 
activation of Foxo1 is correlated with decreased occupancy of CCAAT/Enhancer 
Binding Protein α (C/EBPα) at the albumin promoter.  These results demonstrate 
that serum albumin production is regulated mainly on the transcription level, and 
insulin stimulates albumin expression by inhibiting Foxo1, which acts as a gene 
repressor of albumin by directly or indirectly interfering with C/EBPα binding to 
the albumin promoter. 
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Chapter 1 
General Introduction 
2 
Serum albumin: function, production, and regulation 
Physiological function of serum albumin 
 Albumin is the most abundant plasma protein, accounting for ~60% of all 
proteins in circulation.  Synthesized solely in the liver at a high rate (12-25 grams 
per day in a healthy adult), albumin has important physiological functions and is 
also implicated in various disease states (Fanali et al., 2012).  Serum albumin is 
the main determinant of colloid osmotic pressure and modulates the fluid 
distribution between intravascular and extravascular compartments.  With its 
binding capacity for a myriad of ligands, albumin serves as a key carrier for both 
endogenous biomolecules, including cholesterol, fatty acids, and metal ions, and 
exogenous compounds such as drugs.  In addition, albumin exhibits anti-oxidant 
effects and also functions as a free-radical scavenger to maintain a balanced 
oxidative environment in plasma (Evans, 2002; Fanali et al., 2012; Nicholson, 
2000; Peters, 1995). 
 In the clinical setting, serum albumin is frequently used as a cheap and 
reliable biomarker for various diseases.  For instance, due to its elevated uptake 
into solid tumors and sites with high levels of inflammation, low albumin is proven 
to be a useful indicator for cancer and rheumatoid arthritis.  In addition to its 
application in diagnosis, albumin is often administered to treat and manage 
various diseases including burns, hemorrhage, and liver disease (Evans, 2002; 
Fanali et al., 2012; Nicholson, 2000; Peters, 1995).  Furthermore, albumin has 
the potential to function as an effective drug carrier (Kratz, 2008).  
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Regulation of albumin production 
 The colloid osmotic pressure of the interstitial fluid surrounding the 
hepatocytes is the most important regulator for albumin production.  Indeed, 
intravenous infusion in rats with macromolecules, such as albumin, globulins, 
and dextran, cause a decrease in transcriptional activity of albumin (Pietrangelo 
et al., 1992).  This observation demonstrates an effective feedback mechanism 
to maintain the homeostatic concentration of albumin in circulation.   
 The proper hormonal environment is also essential for optimal albumin 
synthesis.  Insulin is required for adequate albumin synthesis and controls 
albumin production at the transcription level (discussed in more details below).  
Glucocorticoids are also an essential regulator for albumin transcription, as 
adrenalectomized rats exhibit decreased albumin expression (Nawa et al., 1986).  
Consistent with this result, albumin transcription in primary rat hepatocytes can 
be stimulated by dexamethasone treatment (Hutson et al., 1987; Kimball et al., 
1995; Nawa et al., 1986).  Growth hormone, when added to primary hepatocyte 
culture, also has a stimulatory effect on albumin expression (Johnson et al., 
1991).  Albumin synthesis and secretion are inhibited by glucagon (Dich and 
Gluud, 1976; Masumoto et al., 1988; Tavill et al., 1973; Uchida et al., 1991), 
although the inhibitory effect of glucagon on albumin production is likely post 
transcriptional: Nawa et al. found that while glucagon enhances albumin gene 
transcription induced by dexamethasone, glucagon alone has no effect on 
albumin expression (Nawa et al., 1986). 
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 Finally, nutritional state plays a significant role in albumin production.  
Prolonged starvation decreases albumin production in liver (Kelman et al., 1972).  
This is possibly due to limited availability of amino acids under this condition, as it 
was observed that culturing primary rat hepatocytes in amino acids-deficient 
media leads to decreased albumin mRNA and secretion (Hutson et al., 1987; 
Kelman et al., 1972; Nawa et al., 1986).  Among essential amino acids, leucine, 
isoleucine, and tryptophan have stimulatory effects on albumin production 
(Hutson et al., 1987).  Amino acids also regulate albumin synthesis in vivo, as 
rats fed a low-protein diet exhibit reduced albumin expression and protein 
secretion (Nawa et al., 1986).   
 
Regulation of albumin production by insulin 
 Over 30 years ago, Peavy and colleagues found that albumin production 
is significantly reduced in alloxan-induced Type 1 diabetic rats.  Parallel with this 
change, abundance of albumin mRNA in the liver is also reduced.  Administration 
of insulin in these animals can restore both albumin mRNA and secretion (Peavy 
et al., 1978).  A similar observation was made in spontaneously diabetic rats, 
where insulin deficiency causes a decreases in albumin mRNA and synthesis, 
and this defect is eliminated with insulin treatment (Jefferson et al., 1983).  These 
studies highlight the stimulatory effect of insulin on hepatic albumin production by 
regulating the quantity of albumin mRNA. 
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 More biochemical studies have since demonstrated that insulin stimulates 
albumin production on the level of transcription.  Since the apparent half-life of 
albumin mRNA is unaltered in diabetic rats, degradation of mRNA is unlikely to 
be the underlying mechanism.  Furthermore, the size of albumin-synthesizing 
polysomes and the ribosomal half-transit time are comparable between diabetic 
and control rats, suggesting that the translation efficiency of the albumin 
message is not changed (Peavy et al., 1985).  Using primary rat hepatocyte 
culture (Flaim et al., 1985), Lloyd et al. definitely showed that insulin stimulates 
albumin transcription, which directly correlates with albumin mRNA and secretion 
levels (Lloyd et al., 1987). 
 Consistent with observations made in animal models, Type 1 diabetic 
patients undergoing an insulin withdrawal exhibit significantly reduced albumin 
secretion, indicating that insulin positively regulates albumin production in human 
subjects as well (De Feo et al., 1991).  Defects in serum albumin production 
might be specific to the type of diabetes, as the albumin synthetic rate is normal 
in Type 2 diabetic patients, and insulin can stimulate albumin production to the 
same extent in Type 2 diabetic patients as in control subjects (Tessari et al., 
2006b).  This observation suggests that the regulation of albumin production by 
insulin is intact in Type 2 diabetes, which could be explained by the model of 
selective insulin (See Chapter 2, “Discussion”, and Chapter 4, “Serum albumin 
production is intact in Type 2 diabetes”). 
 
Significance 
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 As described previously, serum albumin performs a myriad of important 
physiological functions, including controlling oncotic pressure and modulating 
drug metabolism.  Under conditions of malnutrition, caused by diabetes, 
starvation, or protein deficiency, albumin expression and production are 
decreased.  Hypoalbuminemia, often manifested as swelling, muscular 
symptoms, loss of appetite, ascites, and pleural effusions, would lead to 
dysregulation of albumin-mediated processes.  Since treatment of 
hypoalbuminemia requires treating the underlying cause, it is therefore crucial to 
understand the regulatory mechanism of albumin production in order to devise 
the most effective treatment paradigm.  This study will shed light on the 
molecular basis of how serum albumin production is regulated by insulin.  
 
Insulin signaling and its physiological function 
Overview of the physiological role of insulin 
 Insulin is a pivotal hormone that regulates metabolism and growth 
(Bedinger and Adams, 2015; Biddinger and Kahn, 2006; Saltiel and Kahn, 2001).  
Upon nutrient influx, insulin is secreted from pancreatic β-cells in response to the 
rising blood glucose level.  In peripheral tissues such as fat and muscle, insulin 
stimulates nutrient uptake and storage, while inhibiting nutrient breakdown and 
release.  Specifically, insulin promotes glucose uptake into cells by mediating the 
translocation of the glucose transporter, GLUT4, to the cell membrane.  In 
adipocytes, insulin activates the lipogenic pathway to convert glucose to 
7 
triglycerides for long-term energy storage.  Simultaneously, insulin inhibits 
lipolysis via inactivation of hormone-sensitive lipase (HSL), thereby preventing 
the release of free fatty acids and glycerol into circulation.  In muscle, insulin 
stimulates the net production of glycogen from dietary glucose (Bedinger and 
Adams, 2015; Biddinger and Kahn, 2006; Saltiel and Kahn, 2001).  Liver is 
another major site of insulin action.  Hepatic glucose production is turned off by 
insulin as a result of its inhibition of gluconeogenesis and glycogenolysis.  
Moreover, insulin signaling switches the liver from fatty acids oxidation to a net 
production and secretion of lipids (Bedinger and Adams, 2015; Biddinger and 
Kahn, 2006).  Overall, insulin mediates the whole-body postprandial response 
and maintains glucose and lipid homeostasis. 
  
The insulin signaling pathway 
 The insulin signaling cascade is initiated by insulin binding to its receptor.  
The insulin receptor (IR) is a heterodimeric complex, and each dimer contains an 
α subunit and a β subunit.  The β subunits of IR contain intrinsic tyrosine kinase 
activity that is repressed by the α subunits in the absence of insulin.  Upon insulin 
binding to the α subunits, the β subunits become derepressed and 
transphosphorylate each other, resulting in full activation of IR.  Downstream of 
IR, tyrosine residues on insulin receptor substrate (IRS) are phosphorylated and 
serve as docking sites for proteins containing Src homology 2 (SH2) domains.  In 
the case of insulin signaling, the protein that docks on phosphorylated IRS is 
phosphatidylinositol 3-kinase (PI3K), which phosphorylates phosphoinositides at 
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the 3-position to produce PIP3.  PIP3 binds various signaling molecules via their 
pleckstrin homology (PH) domains, thereby activating them or changing their 
cellular localization.  Downstream of PI3K activation and PIP3 generation, two 
events occur that lead to the activation of Akt or protein kinase B (PKB): First, 
phosphoinositide-dependent kinase 1 (PDK1), the upstream activator of Akt, 
becomes activated as a result of PIP3 accumulation; Second, Akt is recruited to 
the plasma membrane in the vicinity of PDK1 to be phosphorylated at Thr308 
and activated (Biddinger and Kahn, 2006; Saltiel and Kahn, 2001).  The Rictor-
containing mammalian target of rapamycin complex (mTORC2) also directly 
phosphorylates Akt at Ser473 for its full activation (Sarbassov et al., 2005).  
Although phosphorylation at Ser473 is not required for phosphorylation at 
Thr308, mTORC2-mediated phosphorylation seems to determine Akt specificity 
(Jacinto et al., 2006; Shiota et al., 2006).  
 Several pathways downstream of Akt mediate insulin’s effects on 
metabolism.  Akt phosphorylates and inactivates glycogen synthase kinase 3 
(GSK3), relieving the repression on glycogen synthase and thus promoting 
glycogen synthesis (Cross et al., 1995).  On another branch, Akt phosphorylates 
and inactivates the Tuberous Sclerosis 1/2 complex (TSC1/2), thereby releasing 
the inhibition of mammalian target of rapamycin complex 1 (mTORC1) (Inoki et 
al., 2002; Sengupta et al., 2010).  Akt also activates mTORC1 by 
phosphorylating proline-rich Akt substrate of 40kDa (PRAS40), causing it to 
dissociate from mTORC1 and relieving its inhibitory constraint on mTORC1 
activity (Wiza et al., 2012).  In addition to Akt signaling, mTORC1 activity is 
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stimulated by amino acids (Sancak et al., 2010).  AMP-activated protein kinase 
(AMPK), when activated by depleted cellular energy levels, phosphorylates the 
mTOR binding partner Raptor and leads to inactivation of mTORC1 (Gwinn et al., 
2008).  Downstream of insulin signaling, activation of mTORC1 stimulates protein 
synthesis as well as lipogenesis (Düvel et al., 2010; Laplante and Sabatini, 2010; 
Li et al., 2010; Thoreen et al., 2012; Wang and Proud, 2006).  Finally, Akt 
phosphorylates the transcription factor forkhead box O1 (Foxo1), causing its 
translocation out of the nucleus (Biggs et al., 1999; Nakae et al., 1999; Rena, 
2002; Rena et al., 1999).  Foxo1 binds directly to the insulin response elements 
(IREs) in the promoters of key gluconeogenic enzymes to stimulate the 
expression of these genes under fasting conditions.  Under postprandial 
conditions, when insulin is present, Foxo1 is located largely in the cytoplasm and 
thus becomes inactive as a transcription factor (Hall et al., 2000; Schmoll et al., 
2000).  Foxo1 can act as either a transcription activator or a repressor, although 
the detailed mechanism by which it represses gene expression is not yet fully 
understood (see below). 
 
Impairment of insulin signaling and the development of Type 2 diabetes 
 Diabetes is a growing pandemic, affecting about 29 million people in the 
United States and creating a huge economic toll on the health care system.  The 
disease is caused by failed production of (Type 1 diabetes) or dampened 
response to insulin (Type 2 diabetes).  In Type 2 diabetes, insulin action is 
reduced, causing dysregulation of glucose and lipid metabolism.  As a result, 
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Type 2 diabetic patients exhibit hyperglycemia and hyperlipidemia.  To 
compensate for insulin resistance, insulin secretion from the pancreas is 
increased, resulting in hyperinsulinemia.  Although both in vivo and in vitro 
studies have contributed to the understanding of the pathogenesis of insulin 
resistance and Type 2 diabetes, much of this complex metabolic disease remains 
to be understood (Bedinger and Adams, 2015; Biddinger and Kahn, 2006; Saltiel 
and Kahn, 2001).   
 
Foxo1 as a transcriptional repressor 
Overview 
Genetic studies in C. elegans suggest that DAF-16, the Foxo ortholog, 
functions as a transcriptional activator downstream of the insulin/IGF-1 signaling 
(IIS) pathway by binding directly to the insulin response elements (IREs) in the 
promoter.  However, DNA binding is not required for DAF-16 to repress gene 
expression for a different set of genes.  Therefore, genes that are downregulated 
by DAF-16 (Class II genes) are more likely indirect targets (Murphy et al., 2003; 
Schuster et al., 2010; Tepper et al., 2013).  Recently, Tepper et al. described an 
elusive transcriptional activator, PQM-1, that is mutually antagonistic with DAF-
16 with regard to subcellular localization in response to IIS, providing a 
mechanism for the regulation of Class II genes (Tepper et al., 2013).  To date, it 
is unclear whether a similar mechanism exists in mammals.  Recent studies have 
suggested that Foxo1 potentially functions as a repressor indirectly by either 
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inducing the expression of a transcriptional repressor, or modulating the activity 
of another transcription factor. 
 
Foxo1 induces expression of transcription repressors 
Small heterodimer partner (Shp) interacts with and represses a range of 
nuclear receptors and transcription factors including liver X receptor alpha 
(LXRα) and hepatic nuclear factor 4α (Hnf-4α) to regulate cholesterol catabolism 
(Boulias et al., 2005; Huang et al., 2007; Park et al., 2011).  It has been 
demonstrated that Foxo1 directly binds to the promoter of Shp and activates its 
expression (Shin et al., 2012; Wei et al., 2011).  In addition, Shp also plays a role 
in liver metabolism consistent with it being a direct downstream target of Foxo1.  
Shp is induced in ob/ob and diet-induced obese livers.  Shp-transgenic mice 
exhibit elevated hepatic triglyceride and bile acid, whereas Shp-null mice are 
protected from diet-induced obesity and hepatic steatosis.  Furthermore, deletion 
of Shp improves insulin sensitivity and completely reverses hepatic steatosis in 
ob/ob mice (Boulias et al., 2005; Huang et al., 2007; Park et al., 2011).  Another 
transcriptional repressor, inhibitor of DNA binding protein 3 (Id3), a basic helix-
loop-helix (bHLH) protein that forms heterodimer and inhibits other bHLH 
proteins, is also identified as a Foxo1 target that is implicated in liver 
regeneration and development. (Shin et al., 2012).  Interestingly, both Shp and 
Id3 might be involved in the regulation of albumin expression.  Park et al. found 
that Shp physically interacts with C/EBPα, a transcriptional activator known to 
regulate albumin gene expression (see below) and represses its activity (Park et 
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al., 2007).  In chick liver development, Id3 and albumin show reciprocal 
expressions both spatially and temporally (Nakayama et al., 2006).   
 
Foxo1 modulates activity of other transcription factors 
 Ramaswamy et al. first demonstrated that Foxo1 can regulate gene 
expression independent of DNA-binding (Ramaswamy et al., 2002).  Using a 
mutant Foxo1 that lacks DNA binding, the authors identified three classes of 
genes regulated by Foxo1 through transcriptional profiling.  Class I genes are 
induced by Foxo1, and such induction requires DNA binding of Foxo1.  
Interestingly, a Foxo1 mutant lacking DNA-binding is able to induce and repress 
Class II and Class III genes, respectively.  Moreover, chromatin 
immunoprecipitation using an antibody against Foxo1 shows that mutant Foxo1 
is recruited to the promoter of Class II and Class III genes.  These results 
suggest a mechanism where Foxo1 regulates gene expression by interacting 
with other transcription factors at the promoter.  Indeed, it has been since 
discovered that Foxo1 directly interacts with a wide range of transcription factors 
to modulate their activity (Van der Vos and Coffer, 2008).  For example, Foxo1 
antagonizes the transcription activator activity of peroxisome proliferator-
activated receptor γ (PPARγ), a critical regulator of adipocyte differentiation, by 
directly interacting with PPARγ and disrupting its DNA binding to the target genes 
(Dowell, 2003; Fan et al., 2009).  Similarly, Deng et al. recently described a 
mechanism where Foxo1 directly interacts with Srebp-1c and interferes with its 
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binding to the Srebp1c promoter, thereby down regulating lipogenic genes (Deng 
et al., 2012).  
 
Transcription factors known to regulate albumin gene expression 
Overview 
 The promoter region of the albumin gene contains six distinct elements 
(Site A-F), recognized by several transcription factors (Lichtsteiner et al., 1987; 
Maire et al., 1989).  Site B and Site D have the highest activating potential, 
whereas the rest of the sites have much less contribution to the promoter activity.  
Moreover, Site B and Site D interact with liver-enriched transcription factors 
known to regulate albumin gene expression, including hepatocyte nuclear factor 
1α (Hnf-1α), CCAAT/enhancer binding protein α (C/EBPα), C/EBPβ, and D site 
binding protein (Dbp) (Lichtsteiner et al., 1987; Maire et al., 1989). 
 
Hepatic nuclear factor 1α (Hnf-1α) 
 Predominantly expressed in liver and kidney, Hnf-1α is a transcription 
activator known to interact with many liver-specific genes, including albumin 
(Tronche et al., 1989), β-fibrinogen (Courtois et al., 1987), and α1-antitrypsin 
(Courtois et al., 1987; Monaci et al., 1988).  Systemic inactivation of Hnf-1α leads 
to stunted growth and increased mortality.  Hnf-1α is also involved in cholesterol 
and amino acid metabolism, as Hnf1a-deficient mice exhibits severe 
hypercholesterolemia and hyperphenylalanemia.  Importantly, genetic ablation of 
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Hnf1a leads to decreased hepatic expression of albumin as well as lower serum 
albumin level (Lee et al., 1998; Pontoglio et al., 1996).  These observations 
highlight an important regulatory role of Hnf-1α on albumin gene expression.  
 
D site binding protein (Dbp) 
 Dbp, a member of the B-ZIP family, binds to the D site of the albumin 
promoter via its basic domain (Maire et al., 1989; Mueller et al., 1990).  
Interestingly, accumulation of Dbp mRNA and protein follow a “free-running” 
circadian pattern that is independent of feeding and drinking behaviors, where 
Dbp mRNA and protein levels are the highest in the evening and are the lowest 
in the morning (Wuarin and Schibler, 1990).  Since Dbp knockout mice are still 
rhythmic, Dbp is most likely the output of circadian pathway rather than a 
regulator (Lopez-Molina, 1997).  As a result of the circadian pattern of Dbp, 
albumin expression is the most efficient in the evening, as demonstrated by run-
on experiments.  Nevertheless, albumin expression does not fluctuate, probably 
due to the long half-life of its mRNA (Wuarin and Schibler, 1990). 
 
CCAAT/enhancer binding protein α and β (C/EBP α and β) 
 C/EBP α and β are key regulators to control cell differentiation and 
proliferation (Nerlov, 2008).  Highly expressed in liver, adipose, and lung, these 
transcription factors play a significant role in liver metabolism, adipogenesis, 
female fertility, and hermatopoiesis.  Structurally, C/EBPs contain a conserved 
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DNA-binding and dimerization domain, and a C-terminal basic region-leucine 
zipper (bZIP) domain that mediates protein-protein interaction with other 
transcription factors (Nerlov, 2007), which provides an additional layer of 
regulation for C/EBPs function (see below).  In addition, both C/EBPα and 
C/EBPβ exist in multiple isoforms as a result of alternative translation initiation.  
Work by Calkhoven et al. demonstrates that the relative ratio of C/EBP isoforms 
controls cell differentiation and cell fate (Calkhoven et al.). 
 C/EBPα plays a significant role in regulating whole-body metabolism.  
Congenital whole-body Cebpa knockout mice die shortly after birth due to defects 
in glycogen storage in the liver and subsequently hypoglycemia, suggesting that 
C/EBPα is required for mediating energy homeostasis in neonates (Wang et al., 
1995).  In liver, in addition to being a potent trans-activator for the albumin gene 
(Friedman et al., 1989), C/EBPα is also important in other liver functions, 
including bilirubin clearance and ammonia detoxification (Inoue et al., 2004; Y H 
Lee, 1997).  Furthermore, C/EBPα is also a key mediator of glucose and lipid 
metabolism in liver, regulating the expression of gluconeogenic and lipogenic 
enzymes to mediate glycogen synthesis, hepatic glucose production, and lipid 
synthesis in the liver (Inoue et al., 2004; Matsusue et al., 2004; Qiao, 2006; Y H 
Lee, 1997). 
 Often acting together with C/EBPα as a heterodimer, C/EBPβ plays similar 
roles in mediating glucose and lipid metabolism in liver (Croniger et al., 2000; 
1997; Liu et al., 1999; Millward et al., 2007; Rahman et al., 2007; Schroeder-
Gloeckler et al., 2007).  Importantly, C/EBPβ exists in two isoforms: a 35kDa liver 
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activating protein (LAP) and a 20kDa liver inhibitory protein (LIP).  LAP and LIP 
are translated from the same mRNA transcript as a result of leaky ribosome 
scanning.  LIP, lacking the transactivation domain, exhibits higher binding affinity 
for DNA and functions as a dominant inhibitor of C/EBP family members 
(Descombes and Schibler, 1991).  Therefore, the transcriptional activity of a 
C/EBPβ target genes is dependent on the LAP/LIP ratio (Nerlov, 2008; Van der 
Vos and Coffer, 2008).  It has been previously shown that LAP/LIP ratio is altered 
during terminal liver differentiation, ER stress, and inflammation (Hu et al., 2004; 
Li et al., 2008; Luedde et al., 2004).  However, the regulatory mechanism 
controlling the relative synthesis and degradation of LAP and LIP remains 
unclear.  
 
Autophagy and its regulatory role in metabolism 
Overview 
 Autophagy, which translates to “eating oneself”, is an evolutionarily 
conserved quality control process that degrades and recycles damaged cellular 
components and organelles, and the broken-down constituents are in turn used 
for either biosynthesis or energy generation (Kim and Lee, 2014; Rabinowitz and 
White, 2010; Yamada and Singh, 2012).  There are three kinds of autophagy: 
Macroautophagy (referred to as “autophagy” hereafter), characterized by the 
formation of autophagosomes, is responsible for the turnover of organelles and 
proteins.  Microautophagy, on the other hand, involves the formation of single-
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membraned vesicles, which then pinch off within the lysosomal lumen for the 
degradation of the enclosed content (Sahu et al., 2011).  Finally, chaperone-
mediated autophagy is a degradation process selective for soluble cytosolic 
proteins with the KFERQ signature (Arias and Cuervo, 2011).  Under basal 
conditions, constitutive autophagy plays an important housekeeping role to 
maintain cellular functions and energy balance.  In the event of metabolic stress, 
such as starvation, the process of self-cannibalization is a key source of nutrients 
to meet the energy demand.  Recently, numerous studies have demonstrated 
that autophagy is an essential mediator of energy homeostasis, and 
dysregulation of autophagy has direct implications in various diseases including 
metabolic disorders, neurodegenerative diseases, and cancer (Kim and Lee, 
2014; Rabinowitz and White, 2010; Yamada and Singh, 2012).  
 
Autophagy mediates whole-body metabolism 
 Dispensable during embryonic development, autophagy is induced at birth 
in various tissues, including heart, lung, and diaphragm, and remains high for 12 
hours in neonates before returning to basal levels (Kuma et al., 2004).  
Autophagy-deficient mice exhibit significantly reduced level of amino acids and 
die within 1 day of birth (Komatsu, 2005; Kuma et al., 2004; Sou et al., 2008).  
Somewhat surprisingly, blood glucose and lipid levels of autophagy-deficient 
mice are comparable with wildtype littermates, suggesting that in neonates, the 
major role of autophagy is to provide amino acids from breaking down in-house 
proteins (Kuma et al., 2004).  These studies have demonstrated that neonates 
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utilize autophagy to maintain energy balance at birth, when nutrient supply is 
suddenly disrupted.  
 Autophagy has also been implicated in aging.  Well-established regimens 
that extend life span, including caloric restriction, TOR inhibition, and genetic 
manipulation of the insulin signaling cascade, all stimulate the autophagy 
pathway.  Furthermore, in many of these cases, the longevity-promoting effects 
are dependent on autophagy (Madeo et al., 2010; Rubinsztein et al., 2011).  
Recently, Pyo et al. demonstrated that ubiquitous overexpression of Atg5 in mice 
extends lifespan significantly (17.2%), and the animals exhibit a list of anti-aging 
phenotypes such as reduced adiposity, enhanced insulin sensitivity, and 
improved motor function (Pyo et al., 2013).  These observations highlight the 
cytoprotective role of autophagy and further emphasize the important role of 
autophagy in maintaining metabolic homeostasis.  The metabolic role of 
autophagy in adipose tissue and liver is summarized below. 
Autophagy in adipose tissue 
 Autophagy in adipose tissue has a critical role in adipocyte differentiation 
and adipogenesis.  Mice with fat-specific disruption of autophagy are lean and 
exhibit significantly reduced fat mass compared to wild type controls.  
Morphological studies reveal that autophagy-deficient adipocytes are smaller and 
have multilocular lipid droplets, larger cytosol, and increased number of 
mitochondria.  Consistent with increased mitochondrial content, β-oxidation of 
fatty acids is increased in these animals.  Furthermore, white adipose tissue with 
disrupted autophagy exhibit features of brown fat, including increased levels of 
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UCP1.  Due to altered adipose physiology, fat-specific Atg7 knockout mice have 
enhanced insulin sensitivity and are protected from high-fat-diet-induced obesity 
(Singh et al., 2009a; Zhang et al., 2009).   
 Autophagy in adipose tissue is also associated with obesity, insulin 
resistance, and the development of Type 2 diabetes.  In both mice and human, 
autophagy in adipose tissue is elevated in obese subjects compared to lean 
controls.  In addition, when compared to insulin-sensitive subjects, insulin-
resistant individuals exhibit higher levels of autophagic activity in the adipose 
tissue (Jansen et al., 2012; Kovsan et al., 2010).  Consistent with this 
observation, patients with Type 2 diabetes show strongly upregulated autophagy 
in their adipocytes (Anita Öst, 2010).  One proposed mechanism by which 
autophagy contributes to the development of insulin resistance in adipocytes is 
mediating the degradation of insulin receptor, downstream of the elevated level 
of ER stress (Zhou et al., 2009). 
 
Autophagy in liver 
In liver, autophagy mediates energy metabolism in response to hormonal 
signals and nutrient availability (Yin et al., 2008).  Mice with autophagy disrupted 
specifically in the liver exhibit severe hepatomegaly, increased hepatic protein 
content, and accumulation of deformed peroxisomes, mitochondria, and ER, 
suggesting that liver autophagy plays a significant role in the regulation of liver 
mass and the removal of dysfunctional organelles (Komatsu, 2005; Yin et al., 
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2008).  Hepatic autophagy also contributes to the metabolic processes in liver.  
Singh and colleagues discovered that autophagy negatively regulates the 
intracellular lipid stores in liver, a process they referred to as “macrolipophagy”.  
Consistent with this finding, they also observed that disruption of hepatic 
autophagy cause increased hepatic triglyceride content and total lipid droplets in 
hepatocytes (Singh et al., 2009a).  In addition to lipid metabolism, autophagy 
also contributes to glucose production by supplying amino acids as 
gluconeogenic precursors during starvation (Ezaki et al., 2011). 
In addition to having a metabolic role, autophagy also plays a significant 
regulatory role in mediating liver metabolism.  Opposite of what is observed in 
the adipose tissue, hepatic autophagy is suppressed during obesity (Liu et al., 
2009; Singh et al., 2009a; Yang et al., 2010).  This indicates that the metabolic 
function of autophagy is tissue-specific.  Recently, Yang et al. showed that 
suppressing autophagy impairs insulin signaling both in vitro and in vivo, as 
measured by phosphorylation of IR and Akt upon insulin stimulation.  On the 
contrary, inducing hepatic autophagy in leptin-deficient ob/ob mice increases 
insulin signaling, reduces steatosis, and improves systemic glucose homeostasis 
(Yang et al., 2010).  Thus, there might be value in targeting hepatic autophagy as 
a therapeutic intervention against obesity and insulin resistance.   
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Chapter 2 
Insulin stimulates albumin gene expression by inhibiting Foxo1
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Introduction 
 Synthesized solely in the liver, serum albumin is the most abundant 
circulating protein, accounting for ~60% of total serum proteins.  In addition to 
being the major determinant of oncotic pressure, albumin also functions as the 
carrier for many endogenous and exogenous compounds, including free fatty 
acids, ions, and drugs.  Clinically, albumin is a crucial biomarker used to assess 
liver function (Fanali et al., 2012).  Multiple factors, including nutritional states, 
oncotic pressure, and hormonal factors, regulate albumin production (Kimball et 
al., 1995; Pietrangelo et al., 1992; Sakuma et al., 1987).  In Type 1 diabetes, the 
concentration of albumin in blood is decreased, and administration of insulin is 
required to prevent hypoalbuminemia (De Feo et al., 1991; Jefferson et al., 
1983).  Early biochemical studies have shown that insulin stimulates albumin 
production in the liver by activating gene transcription (De Feo et al., 1991; Flaim 
et al., 1985; Hutson et al., 1987; Jefferson et al., 1983; Kimball et al., 1995; Lloyd 
et al., 1987; Peavy et al., 1978; 1985).  Yet, the detailed pathway by which insulin 
exerts this effect has not been described.  
In liver, insulin promotes protein production and lipid synthesis, while 
turning off gluconeogenesis and glycogenolysis (Brown and Goldstein, 2008; 
Cross et al., 1995; Leavens and Birnbaum, 2011; Saltiel and Kahn, 2001).  The 
insulin signaling pathway has been well characterized: insulin binds to the insulin 
receptor (IR), which leads to phosphorylation of the insulin receptor substrate 
(IRS).  This then initiates a cascade of signaling events that results in the 
phosphorylation and activation of Akt protein kinases (Saltiel and Kahn, 2001).  
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Several pathways downstream of Akt mediate insulin’s effects on metabolism.  
Akt phosphorylates and inactivates the Tuberous Sclerosis 1/2 (TSC1/TSC2) 
complex, thereby releasing the inhibition of mammalian target of rapamycin 
complex 1 (mTORC1) (Inoki et al., 2002; Sengupta et al., 2010).  Activation of 
mTORC1 stimulates protein synthesis as well as lipogenesis (Düvel et al., 2010; 
Laplante and Sabatini, 2010; Li et al., 2010; Thoreen et al., 2012; Wang and 
Proud, 2006).  Akt also phosphorylates the transcription factor forkhead box O1 
(Foxo1), causing its translocation out of the nucleus (Biggs et al., 1999; Nakae et 
al., 1999; Rena, 2002; Rena et al., 1999).  Foxo1 binds directly to the insulin 
response elements (IREs) in the promoters of key gluconeogenic enzymes to 
stimulate the expression of these genes under fasting conditions.  Under 
postprandial conditions when insulin is present, Foxo1 is located largely in the 
cytoplasm and thus becomes inactive as a transcription factor (Hall et al., 2000; 
Schmoll et al., 2000).  
Autophagy, literally translated as “self-eating”, is a mechanism where 
cellular constituents are engulfed in compartments called autophagosomes and 
delivered to the lysosome for degradation.  Since its first description by de Duve 
and Wattiaux in 1966, autophagy has been extensively characterized.  
Autophagy has been implicated in human pathology, including 
neurodegenerative disease, cancer, and aging (Rabinowitz and White, 2010; 
Rubinsztein et al., 2011; Yamada and Singh, 2012).  Moreover, autophagy is 
emerging as a critical component in the regulation of metabolism, as recent 
studies demonstrate its role in lipid and glucose metabolism (He et al., 2012; Liu 
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et al., 2009; Singh et al., 2009b; Yang et al., 2010).  Furthermore, autophagy has 
been linked with pancreatic beta cell function and insulin action (Ebato et al., 
2008; Jung et al., 2008). These observations suggest that autophagy, in addition 
to its cytoprotective role, is also an important metabolic modulator. 
In the present study, we used a genetic approach to address the 
longstanding question of the mechanism by which insulin stimulates albumin 
transcription.  We found that insulin acts directly on the liver through the 
IR/PI3K/Akt pathway to inhibit Foxo1, which functions as a repressor of albumin 
expression.  Interestingly, elevated hepatic autophagy also contributes to serum 
albumin production, possibly by supplying amino acid, generating energy, and/or 
augmenting protein secretion. 
 
Results 
Albumin gene expression is reduced in Type 1, but not Type 2, diabetic livers 
First, we assessed the effect of diabetes on albumin expression in mice.  
Steptozotocin (STZ), a compound that induces β-cell death, is frequently used to 
induce Type 1 diabetes in animal models.  Mice injected with STZ developed 
severe hyperglycemia (Figure 2.1A) and lost a significant amount of body weight 
(Figure 2.1B).  In addition, albumin gene expression in liver was significantly 
decreased compared to control animals (Figure 2.1C).  Consistent with early 
studies in rats, this result suggests that insulin positively regulates hepatic 
albumin production on the level of transcription.  We did not observe a difference 
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in serum albumin level between STZ-treated and control animals (not shown), 
possibly because the half-life of albumin protein is longer than the duration of the 
experiment (21 days and 11 days, respectively).  
 Next, we used the leptin-deficient (ob/ob) mouse model to address 
whether albumin production is also reduced in Type 2 diabetes.  Interestingly, 
despite of having severe insulin resistance, ob/ob animals exhibited slightly 
elevated level of total serum protein and albumin gene expression compared to 
control (Figure 2.2 A and B).  These results suggest that albumin transcription 
and production are slightly increased in Type 2 diabetic livers. 
 
Insulin signals directly on the liver to stimulate albumin gene expression 
 To assess whether the regulation of insulin on albumin production is a 
cell-autonomous effect, we deleted insulin receptor (Ir) specifically in the liver 
(IRKO, Figure 2.3A).  Serum albumin level was significantly reduced in IRKO 
animals compared to controls (GFP, Figure 2.3B).  Consistent with the reduced 
circulating albumin protein level, albumin gene expression in IRKO livers was 
significantly decreased compared to controls (Figure 2.3C).  These results 
suggest that insulin controls albumin production by signaling directly on the liver.  
 It is also worthwhile to note that a short-term (overnight) fast did not affect 
the steady-state serum albumin level or albumin expression level in either IRKO 
or control livers, as there was no significant difference between the overnight-
fasted state and the fasted-refed state (Figure 2.3B and C).  Rather than 
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measuring the newly synthesized species, here, total albumin protein and mRNA 
levels were measured.  Since the half-life of these species exceeds the duration 
of overnight fasting, the stimulatory effect of insulin on albumin expression and 
protein level could not be observed.  
 
Akt is required for proper albumin gene expression and production 
 Akt is an essential downstream signaling molecule that mediates various 
metabolic effects of insulin.  We then investigated whether Akt is required to 
regulate albumin production downstream of IR.  To this end, we deleted the only 
isoforms of Akt expressed in liver, Akt1 and Akt2, specifically in the liver 
(AktDKO, Figure 2.4A).  AktDKO mice exhibited a 50% reduction in serum 
albumin compared to control (GFP, Figure 2.4B).  This severe hypoalbuminemia 
was correlated with a dramatic decrease in albumin gene expression (Figure 
2.4C). 
 To address whether this albumin production defect is cell-autonomous, we 
isolated primary hepatocytes from GFP and AktDKO mice and measured 
albumin secretion in vitro.  AktDKO hepatocytes secreted significantly less 
albumin compared to control (Figure 2.4D).  Consistent with the reduced albumin 
secretion, albumin gene expression in AktDKO hepatocytes was significantly 
decreased (Figure 2.4E).  Taken together, these results suggest that insulin 
signals through the Akt pathway to control albumin transcription and secretion. 
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Inhibition of Foxo1 is required for proper albumin expression and production 
 Foxo1, the transcription factor downstream of Akt, becomes constitutively 
active when insulin signaling is disrupted.  We asked whether inhibition of Foxo1 
as a result of insulin signaling is required for maintaining albumin transcription. 
Interestingly, additional deletion of Foxo1 in IRKO livers (FoxoDKO, Figure 2.5A) 
fully restored the reduced circulating albumin level observed in IRKO mice 
(Figure 2.5B).  In addition, albumin expression in FoxoDKO livers was completely 
restored to control levels (Figure 2.5C). 
 Similarly, additional deletion of Foxo1 in AktDKO livers (FoxoTKO, Figure 
2.6A) almost completely restored serum albumin level (Figure 2.6B), and 
completely restored the reduced albumin expression observed in AktDKO livers 
(Figure 2.6C).  This effect was cell-autonomous: primary hepatocytes isolated 
from FoxoTKO livers exhibited comparable albumin secretion (Figure 2.6D) and 
albumin gene expression (Figure 2.6E) as control.  These results suggest that 
insulin controls albumin transcription and secretion via, at least in part, the 
inhibition of Foxo1. 
 We then investigated whether inhibiting Foxo1 is sufficient to correct the 
reduced albumin expression in Type 1 diabetic livers.  To this end, we used STZ 
to induce diabetes in either control (GFP) or liver-specific Foxo1 knockout mice 
(FoxoKO, Figure 2.7A).  Both genotypes developed severe hyperglycemia post 
STZ injection (Figure 2.7B).  Importantly, STZ treatment in GFP mice caused a 
50% reduction in albumin gene expression in liver, and this reduction was 
completely absent in FoxoKO mice (Figure 2.7C).  In addition, we found that 
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transgenic mice expressing a constitutively active Foxo1 (CA-Foxo1) had 
significantly reduced hepatic albumin expression compared to wildtype controls 
(WT, Figure 2.8).  These results suggest that constitutive activation of hepatic 
Foxo1 is sufficient to repress albumin expression and contributes to decreased 
albumin production in Typ1 diabetes.  
 
Whether mTORC1 is required for proper albumin production is unclear 
 In addition to inhibiting Foxo1, Akt also phosphorylates and inhibits TSC1 
to activate mTORC1, a major regulator for protein translation by activating S6 
kinase.  To investigate whether mTORC1 signaling also contributes to albumin 
production, we first assessed the effect of restoring the reduced hepatic 
mTORC1 activity in AktDKO mice. To this end, we concomitantly deleted Tsc1 to 
generate liver-specific Tsc1/Akt1/Akt2 triple-knockout mice (TSC1TKO, Figure 
2.9A).  As indicated by the constitutively elevated levels of ribosomal protein S6 
phosphorylation, mTORC1 in these livers was constitutively active in the absence 
of hepatic Akt activity, regardless of the nutritional state (Figure 2.9A).  While 
TSC1TKO animals exhibited significantly reduced serum protein level when 
compared to GFP controls, the defect was much milder than AktDKO animals 
(~25% vs. 50% reduction, Figure 2.9B).  Furthermore, concomitant deletion of 
Tsc1 showed no improvement on the reduced albumin gene expression 
observed in Akt-null livers (Figure 2.9C).  These results suggest that mTORC1 
signaling might contribute to hepatic albumin production post-transcriptionally. 
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 However, we obtained a contradictory result when we directly examined 
the role of mTORC1 signaling on albumin production by deleting Raptor, an 
essential component of mTORC1, specifically in the liver (RaptorKO, Figure 
2.10A).  The absence of mTORC1 activity was confirmed by the complete lack of 
phosphorylated S6.  In addition, as a result of decreased negative feedback 
mediated by S6 kinase, Akt was hyper-phosphorylated in RaptorKO livers (Figure 
2.10A).  Both total serum protein concentration and albumin gene expression 
level of RaptorKO mice were comparable to GFP controls (Figure 2.10B and C).  
These results suggest that mTORC1 activity is not required to maintain hepatic 
albumin production.  
 
Elevated hepatic autophagy contributes to albumin production 
 Downstream of insulin/Akt signaling, mTORC1 inhibits autophagy, a 
process important for cellular renewal and waste disposal.  Recent studies have 
shown that autophagy also plays a significant role in metabolic regulation and 
insulin action.  Since mice lacking Akt in the liver exhibited impaired mTORC1 
activity, hepatic autophagy in these animals was elevated, as indicated by the 
reduced level of p62, a protein degraded by autophagy (Figure 2.11).  We then 
asked whether elevated autophagy contributes to the reduced albumin 
production in AktDKO animals. 
 First, we assessed the role of hepatic autophagy on albumin production in 
wildtype animals.  To this end, we deleted Atg5, an essential component of the 
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autophagy pathway, specifically in the liver.  Liver-specific Atg5 knockout 
(Atg5KO) animals exhibited normal blood glucose level and body weight (Figure 
2.12A and B).  Consistent with previous observations in models with disrupted 
hepatic autophagy, Atg5KO mice exhibited elevated liver weight compared to 
GFP controls (Figure 2.12C and D).  Interestingly, Atg5KO mice showed a small 
decrease in total serum protein concentration in the overnight-fasted state but not 
in the fasted-refed state (Figure 2.12E).  Since autophagy is elevated during 
fasting, this result suggests that active hepatic autophagy might contribute to 
albumin production.  Furthermore, albumin gene expression in Atg5KO mice was 
normal (Figure 2.12F), suggesting that the role of autophagy on albumin 
production is post-transcriptional.  
 Next, we assessed the effect of elevated hepatic autophagy in AktDKO 
mice on albumin production.  To this end, we concomitantly deleted Atg5 and 
generated liver-specific Atg5/Akt1/Akt2 triple-knockout mice (Atg5TKO, Figure 
2.13A).  Interestingly, Atg5TKO mice developed severe edema, accumulating a 
significant amount of fluid in the interstitial space (Figure 2.13B), indicating 
severe dysregulation of oncotic pressure, most likely due to defects in albumin 
production.  Atg5TKO mice exhibited normal fasting glucose level and 
significantly increased body weight (Figure 2.13C and D).  The body weight 
difference was mostly due to fluid accumulation (Figure 2.13E).  Interestingly, the 
liver weight of Atg5TKO mice was comparable to GFP controls (Figure 2.13F).  
Since AktDKO livers were smaller, this result is consistent with previous 
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observation that disrupting hepatic autophagy leads to an increase in liver 
weight. 
 Disrupting hepatic autophagy in AktDKO livers exacerbated the reduced 
serum protein level (Figure 2.14A), consistent with the severe edema phenotype 
observed in Atg5TKO animals.  Surprisingly, concomitant deletion of Atg5 not 
only completely restored the reduced albumin gene expression observed in 
AktDKO livers, albumin mRNA levels in these livers were even slightly increased 
compared to GFP controls (Figure 2.14B). 
 
Discussion 
 Early biochemical studies in rats have shown that insulin stimulates 
albumin production in liver by activating gene transcription (De Feo et al., 1991; 
Flaim et al., 1985; Hutson et al., 1987; Jefferson et al., 1983; Kimball et al., 1995; 
Lloyd et al., 1987; Peavy et al., 1978; 1985).  Similarly, mice with STZ-induced 
Type 1 diabetes exhibited significantly reduced albumin gene expression 
compared to control (Figure 2.1C).  Yet, the detailed pathway via which insulin 
regulates albumin gene expression has not been described.  Here, we used a 
genetic approach to systematically elucidate this pathway. 
 Deletion of the insulin receptor specifically in the liver led to a decrease in 
both albumin gene expression and circulating albumin levels (Figure 2.3A and B), 
suggesting that insulin signals directly on the liver to control albumin production.  
This is consistent with previous observations described in Michael et al., where 
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the liver-specific congenital Ir-knockout mice exhibit a 50% reduction in serum 
albumin compared to wildtype control (Michael et al., 2000).  The defect in our 
IRKO mice was much milder (~25% reduction, Figure 2.3B), possibly because 
our knockout model was acute and the animals were much younger (3 months 
old vs. 6 months old).   
 Disruption of both isoforms of hepatic Akt specifically in the liver also 
caused a significant reduction in both albumin gene expression and circulating 
albumin levels (Figure 2.4A and B), suggesting that Akt is required downstream 
of IR to mediate insulin’s effect on albumin production.  Importantly, when 
compared to the IRKO, AktDKO mice exhibited a larger defect, suggesting that 
basal hepatic Akt activity in IRKO mice maintained some albumin gene 
expression and protein production.  Furthermore, Akt regulates albumin 
production cell-autonomously, as hepatocytes isolated from AktDKO animals 
exhibited decreased albumin gene expression and secreted less albumin protein 
in vitro compared to control (Figure 2.4D and E). 
 To interrogate how albumin production is regulated downstream of Akt, we 
first examined the role of Foxo1, a transcription factor phosphorylated and 
inhibited by Akt.  Foxo1 is an important target whose inhibition mediates many of 
the actions of insulin.  Liver-specific Foxo1 knockout mice phenocopy the effect 
of insulin in having impaired glucose production (Matsumoto et al., 2007).  In 
addition, inhibition of hepatic Foxo1 activity protects against high-fat diet induced 
hepatic insulin resistance (Kim et al., 2009; Xiong et al., 2013).  On the other 
hand, transgenic mice with liver-specific expression of constitutively active Foxo1 
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exhibit fasting hyperglycemia, reduced de novo lipogenesis and hepatic insulin 
resistance (Zhang et al., 2006).  These studies highlight that Foxo1 plays a 
significant role in regulating glucose and lipid metabolism downstream of insulin 
in liver.  Here, we found that active Foxo1 also represses albumin expression.  In 
models where Foxo1 was constitutively active (IRKO, AktDKO, STZ-induced 
diabetes), albumin gene expression was decreased and genetic ablation of 
Foxo1 in these models completely restored the decreased albumin expression 
(Figure 2.5, Figure 2.6, and Figure 2.7).  Furthermore, we demonstrated that 
constitutive activation of Foxo1 in liver was sufficient to decrease albumin gene 
expression (Figure 2.8).  Taken together, we conclude that insulin stimulates 
albumin production by inhibiting Foxo1, which represses albumin expression. 
 Interestingly, even though concomitant deletion of Foxo1 completely 
restored the reduced albumin gene expression in AktDKO livers, there remained 
a small, yet statistically significant decrease in albumin protein level in serum, 
suggesting that insulin may also regulate albumin production at a post-
transcriptional site downstream of Akt.  To this end, we investigated the role of 
mTORC1, a complex known to stimulate protein translation downstream of 
insulin, in serum albumin production.   
Impaired mTORC1 activity in AktDKO liver also contributed to decreased 
albumin production because when we restored mTORC1 activity by deleting 
Tsc1 in addition to Akt1 and Akt2 specifically in the liver, serum albumin level 
increased from 50% of control level to 75% of control (Figure 2.9B).  mTORC1 
contributed to albumin production on a post-transcription level, as albumin gene 
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expression was not affected by restoring hepatic mTORC1 activity (Figure 2.9C).  
Taken together, these results suggest that downstream of Akt, albumin gene 
expression is controlled by Foxo1, whereas mTORC1 may contribute to post-
transcriptional production of serum albumin, presumably on the level of protein 
translation and/or secretion.  Similarly, disrupting mTORC1 activity by deleting 
Raptor specifically in the liver had no effect on albumin gene expression (Figure 
2.10C).  Surprisingly, serum protein level was not significantly reduced in the 
absence of hepatic mTORC1 activity (Figure2.10B).  At first glance, results in 
TSC1TKO and RaptorKO livers seem to be inconsistent with regard to whether 
mTORC1 contributes to serum albumin production.  We speculate that normal 
serum albumin level in RaptorKO animals might be the result of elevated hepatic 
autophagy, which also contributes to albumin production (see below).  
Nevertheless, mTORC1 exerts a relatively minor effect on serum albumin 
production, suggesting that regulation of albumin transcription plays a more 
dominant role than translational regulation in serum albumin production. 
 Autophagy is an important physiological process that maintains energy 
balance, disposes misfolded proteins, and removes damaged cellular 
compartments.  Autophagy is activated by increased cellular stress and inhibited 
by activation of mTORC1 (Rabinowitz and White, 2010; Yamada and Singh, 
2012).  As a result of dampened mTORC1 activity in AktDKO livers, autophagy 
was elevated, as indicated by the decreased level of p62, a protein degraded by 
autophagy (Figure 2.11).  We asked whether increased autophagy contributed to 
the reduced production of albumin observed in AktDKO animals. 
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 Our results indicate that in postprandial state, autophagic activity is low 
and exerts little effect on albumin production.  On the other hand, we observed a 
small yet statistically significant decrease in serum protein level in overnight 
fasted Atg5KO animals (Figure 2.12E), suggesting that opposite to what we 
expected, hepatic autophagy, a catabolic process, positively contributes to serum 
albumin production.  Furthermore, this level of regulation occurred at a post-
transcriptional site, as disruption of hepatic autophagy did not affect albumin 
gene expression level (Figure 2.12F).  
 Deletion of Atg5 in addition to Akt1 and Akt2 specifically in the liver 
(Atg5TKO) led to the development of severe edema.  Atg5TKO mice 
accumulated significant amount of fluid (equivalent to a third of body weight) in 
the interstitial space (Figure 2.13B-E), suggesting that oncotic pressure in these 
animals was severely dysregulated.  Atg5TKO animals exhibited normal liver 
weight compared to controls (Figure 2.13F).  Since Akt-null livers were smaller 
than controls, this implies that disruption of hepatic autophagy in this model also 
induced hepatomegaly.  Consistent with the edema phenotype, serum protein of 
Atg5TKO animals was significantly reduced compared to controls (Figure2.14A).  
Interestingly, this reduction was exacerbated compared to AktDKO animals 
(~70% reduction vs. ~50% reduction, respectively), suggesting that activation of 
autophagy in AktDKO livers maintained some albumin production.  This is 
consistent with our previous observation, where activation of hepatic autophagy 
during fasting positively contributed to albumin production.   
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 How hepatic autophagy contributes to albumin production is currently 
unclear.  One possible mechanism is that autophagy generates substrates 
intracellularly to supply protein synthesis, since amino acids released from 
autophagic degradation can potentially be recycled for protein production (Narita 
et al., 2011; Rabinowitz and White, 2010).  In addition, it is possible that the 
products of autophagic degradation are used for energy generation to support 
hepatic protein production (He et al., 2012; Rabinowitz and White, 2010; Singh et 
al., 2009b).  It has been demonstrated recently that autophagy is also involved in 
both conventional and unconventional secretory pathways.  Notably, in 
senescent cells, autophagosomes co-localize with mTORC1 to form the TOR-
autophagy spatial coupling compartment (TASCC).  This co-localization allows 
for spatial coupling of autophagic degradation, which generates a high flux of 
substrates, directly with mTORC1-mediated biosynthesis for efficient synthesis 
and secretion of proteins in these cells (Narita et al., 2011).  It is possible that 
such compartment also exists in liver, and autophagy contributes to albumin 
production by augmenting its secretion. 
Somewhat surprisingly, we also observed disconnect between serum 
albumin level and albumin gene expression in Atg5TKO animals.  Specifically, 
even though serum protein levels in these animals were dramatically decreased, 
hepatic albumin mRNA was slightly increased compared to controls (Figure 
2.14B).  We speculate this is the result of the feedback mechanism in response 
to the drastic decrease in oncotic pressure, the main regulator of albumin 
synthesis (Fanali et al., 2012; Nicholson, 2000).  It has been shown that 
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intravenous infusion of macromolecules in rats can decrease the transcriptional 
activity of albumin to compensate for the increase in oncotic pressure 
(Pietrangelo et al., 1992).  In Atg5TKO animals, oncotic pressure was 
significantly reduced as a result of severely reduced albumin production, and it is 
possible that albumin transcription was stimulated as a compensatory 
mechanism.  It is important to note that under this model, oncotic pressure 
regulates albumin transcription by a pathway independent of Akt. 
In contrast to what was observed in STZ-induced Type 1 diabetic animals, 
serum albumin production and transcription are slightly elevated in leptin-
deficient animals, suggesting differential regulation of albumin by insulin in Type 
1 versus Type 2 diabetes.  Consistent with this result, studies in human patients 
also showed that serum albumin production is not affected by Type 2 diabetes 
(Tessari et al., 2006b).  The increased albumin expression and protein level in 
leptin-deficient animals are likely the compensatory induction as a result of 
albuminuria in these animals (Hudkins et al., 2010; Tessari et al., 2006a).  
Alternatively, our result suggests that insulin action on serum albumin production 
is maintained during insulin resistance, and the increased albumin gene 
expression could be the result of hyperinsulinemia in these animals.  During 
insulin resistance, insulin’s ability to stimulate glucose uptake and to inhibit 
hepatic glucose production is impaired, yet insulin continues to stimulate de novo 
lipogenesis, resulting hypertriglyceridemia. Currently, there are two prevailing 
views to explain the paradoxical pathology of metabolic disease.  Under the 
model of “selective insulin resistance”, only specific metabolic pathways are 
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resistant to insulin while the others remain intact: insulin fails to suppress hepatic 
glucose production, while continuing to sustain hepatic lipogenesis (Brown and 
Goldstein, 2008).  It is possible that in Type 2 diabetes, the regulation of insulin 
on albumin production also remains intact.  An alternative model suggests that 
rather than impaired insulin action, the metabolic defects are mainly caused by 
altered substrate delivery and nutrient handling (Otero et al., 2014). Under this 
model, our result would imply that transcription and secretion of serum albumin is 
unaffected by altered nutrient flux to the liver during insulin resistance. 
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Figures 
 
 
 
Figure 2.1: Albumin expression is decreased in Type 1 diabetic livers. 
A,B. (A) Blood glucose and (B) body weight of mice that received an intra-
peritoneal injection of either control buffer (Ctrl) or Steptozotocin (STZ) at 200mg 
per kg body weight.  
C. Hepatic albumin mRNA level measured 9 days post STZ injection. 
All values are expressed as mean ± SEM. n = 3-5; *p<0.05 vs. Ctrl by two-tailed 
Student’s t-test.  
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Figure 2.2: Albumin expression and production are normal in Type 2 
diabetic livers. 
A. Total protein concentration in serum of wildtype (WT) and leptin-deficient 
(ob/ob) mice. 
B. Hepatic albumin mRNA levels of WT and ob/ob mice.  
All values are expressed as mean ± SEM. n = 4-5; *p<0.05 vs. WT and **p<0.01 
vs. WT by two-tailed Student’s t-test. 
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Figure 2.3: Insulin signals directly in the liver to stimulate albumin 
expression.  
A. Western blots for insulin receptor (IR) and actin in liver homogenates of GFP 
control (GFP) and liver-specific Ir knockout (IRKO) animals. 
B,C. Serum albumin concentration (B) and hepatic albumin mRNA level (C) in 
GFP and IRKO animals that had been either fasted overnight or fasted overnight 
and refed for 4 hours.  
All values are expressed as mean ± SEM. n = 3-6; **p<0.01 vs. GFP and 
***p<0.001 vs. GFP by two-way ANOVA using Sidak post-test. 
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Figure 2.4: Akt is required to mediate insulin’s effect on albumin 
production. 
A. Western blots for Akt1, Akt2, and actin in liver homogenates of GFP control 
(GFP) and liver-specific Akt1/Akt2 double-knockout (AktDKO) animals. 
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B,C. Serum albumin concentration (B) and hepatic albumin mRNA level (C) in 
GFP and AktDKO animals that had been either fasted overnight or fasted 
overnight and refed for 4 hours. n = 3-4; **p<0.01 vs. GFP by two-way ANOVA 
using Sidak post-test. 
D. A representative experiment of in vitro albumin secretion assay. Primary 
hepatocytes isolate from GFP and AktDKO livers were cultured in serum-free 
media for 2 hours. Secreted proteins were TCA precipitated and subjected to 
Western blot for albumin. Experiment was repeated 3 times. 
E. Albumin mRNA level in primary hepatocytes isolated from GFP and AktDKO 
livers were assayed by RT-qPCR. n = 3-4; **p<0.01 vs. GFP by two-tailed 
Student’s t-test. 
All values are expressed as mean ± SEM. 
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Figure 2.5: Inhibition of Foxo1 restores reduced albumin production in 
liver-specific insulin receptor knockout mice. 
A. Western blots for insulin receptor (IR), Foxo1, and actin in liver homogenates 
of GFP control (GFP) and liver-specific Ir/Foxo1 double-knockout (FoxoDKO) 
animals. 
B,C. Serum albumin concentration (B) and hepatic albumin mRNA level (C) in 
GFP, liver-specific Ir knockout (IRKO), and FoxoDKO animals that had been 
either fasted overnight or fasted overnight and refed for 4 hours. 
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All values are expressed as mean ± SEM. n = 4-5; ns, not significant, *p<0.05 vs. 
GFP, and ***p<0.001 vs. WT by two-way ANOVA using Sidak post-test. 
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Figure 2.6: Inhibition of Foxo1 restores reduced albumin production in 
liver-specific Akt1/Akt2 double-knockout mice. 
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A. Western blots for Akt1, Akt2, Foxo1, and actin in liver homogenates of GFP 
control (GFP) and liver-specific Akt1/Akt2/Foxo1 triple-knockout (FoxoTKO) 
animals.  
B,C. Serum albumin concentration (B) and hepatic albumin mRNA level (C) in 
GFP, liver-specific Akt1/Akt2 double-knockout (AktDKO), and FoxoTKO animals 
that had been either fasted overnight or fasted overnight and refed for 4 hours. n 
= 3-5; ns, not significant, **p<0.01 vs. GFP, and ***p<0.001 vs. GFP by two-way 
ANOVA using Sidak post-test. 
D. A representative experiment of in vitro albumin secretion assay. Primary 
hepatocytes isolated from GFP and FoxoTKO livers were cultured in serum-free 
media for 2 hours. Secreted proteins were TCA precipitated and subjected to 
Western blot for albumin. Experiment was repeated 3 times. 
E. Albumin mRNA level in primary hepatocytes isolated from GFP and FoxoTKO 
livers were measured by RT-qPCR. n = 3-4; ns, not significant by two-tailed 
Student’s t-test. 
All values are expressed as mean ± SEM. 
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Figure 2.7: Inhibition of Foxo1 restores reduced albumin expression in 
streptozotocin-induced Type 1 diabetic livers. 
A. Western blots for Foxo1 and lamin in liver nuclear extracts of GFP control 
(GFP) and liver-specific Foxo1 knockout (FoxoKO) animals. 
B,C. Blood glucose (B) and hepatic albumin mRNA level (C) of GFP and FoxoKO 
animals 9 days post an intra-peritoneal injection of either buffer (Ctrl) or 
streptozotocin (STZ) at 200mg per kg body weight. 
All values are expressed as mean ± SEM. n = 5-7; ns, not significant, **p<0.01 
vs. Ctrl and ***p<0.001 vs. Ctrl by two-way ANOVA using Sidak post-test. 
A
Foxo1
Lamin
GFP FoxoKO
Ctrl STZ
GFP FoxoKO
0.0
0.5
1.0
1.5
Alb mRNA
Fo
ld
 C
ha
ng
e
Ctrl
STZ
**
ns
Blood Glucose
GFP FoxoKO
0
200
400
600
m
g/
dl
Ctrl
STZ
*** ***
Ctrl STZ
B C
49 
 
 
Figure 2.8: Activation of hepatic Foxo1 is sufficient to suppress albumin 
expression. 
Hepatic albumin mRNA level of wildtype (WT) and liver-specific transgenic mice 
expressing a constitutively active Foxo1 (CA-Foxo1) were measured by RT-
qPCR. 
All values are expressed as mean ± SEM. n = 3; **p<0.01 vs. WT by two-tailed 
Student’s t-test.  
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Figure 2.9: Activation of mTORC1 partially restores reduced albumin 
production in liver-specific Akt1/Ak2 double-knockout mice with no effect 
on albumin gene expression.  
A. Western blots for tuberculosis sclerosis complex (TSC) 1, TSC2, 
phosphorylated Akt (S473), Akt2, phosphorylated ribosomal protein S6 
(S235/S236), and ribosomal protein S6 in liver homogenates of GFP control 
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(GFP) and liver-specific Tsc1/Akt1/Akt2 triple-knockout (TSC1TKO) animals that 
had been either fasted overnight or fasted overnight and refed for 4 hours.  
B-D. Total protein concentration in serum (C) and albumin mRNA level (D) in 
GFP and TSC1TKO animals that had been either fasted overnight or fasted 
overnight and refed for 4 hrs. 
All values are expressed as mean ± SEM. n = 4-5; ns, not significant and 
***p<0.001 vs. GFP by two-way ANOVA using Sidak post-test. 
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Figure 2.10: mTORC1 is not required for proper hepatic albumin 
production. 
A. Western blots for Raptor, phosphorylated Akt (S473), phosphorylated 
ribosomal protein S6 (S235/S236), ribosomal protein S6, and tubulin in liver 
homogenates of GFP control (GFP) and liver-specific Raptor knockout 
(RaptorKO) animals that had been either fasted overnight or fasted overnight and 
refed for 4 hours. 
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B,C. Total protein concentration in serum (B) and hepatic albumin mRNA level 
(C) of GFP and RaptorKO animals. 
All values are expressed as mean ± SEM. n = 9; *p<0.05 vs. GFP and 
***p<0.001 vs. GFP by two-tailed Student’s t-test. 
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Figure 2.11: Disruption of Akt signaling in the liver leads to elevated 
hepatic autophagy. 
Immunohistochemical staining for p62, a protein degraded by autophagy, in GFP 
control (GFP) and Akt-null (AktDKO) livers. Scale bars indicate 100µm. 
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Figure 2.12: Disruption of hepatic autophagy in wildtype mice has no effect 
on albumin production.  
Blood glucose (A), body weight (B), liver weight (C), liver weight as a percent of 
body weight (D), total protein concentration in serum (E), and hepatic albumin 
mRNA level (F) of GFP control (GFP) or liver-specific Atg5 knockout (Atg5KO) 
mice that had been either fasted over night or fasted overnight and refed for 4 
hours. 
All values are expressed as mean ± SEM. n = 4-5; ns, not significant, *p<0.05 vs. 
GFP, **p<0.01 vs. GFP, and ***p<0.001 vs. GFP by two-way ANOVA using 
Sidak post-test. 
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Figure 2.13: Disruption of hepatic autophagy in liver-specific Akt1/Akt2 
double-knockout mice causes severe edema. 
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A. Western blots for Atg5, p62, Akt2, and ribosomal protein S6 in liver 
homogenates of GFP control (GFP) and liver-specific Atg5/Akt1/Akt2 triple-
knockout (Atg5TKO) animals.  
B. Gross appearance of the peritoneal cavity of GFP and Atg5TKO mice. 
C-F. Fasting blood glucose (C), body weight (D), skin and fluid weight (E, 
obtained by subtracting the weight of dissected carcass from body weight), and 
liver weight (F) of GFP and Atg5TKO mice. 
All values are expressed as mean ± SEM. n = 6-9; ns, not significant and 
***p<0.001 vs. GFP by two-tailed Student’s t-test. 
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Figure 2.14: Disruption of hepatic autophagy in liver-specific Akt1/Akt2 
double-knockout mice restores reduced albumin expression but not 
reduced circulating albumin. 
Total protein concentration in serum (A) and hepatic albumin mRNA level (B) in 
GFP control (GFP) and liver-specific Atg5/Akt1/Akt2 triple-knockout (Atg5TKO) 
mice.  
All values are expressed as mean ± SEM. n = 6-9; *p <0.05 vs. GFP and 
***p<0.001 vs. GFP by two-tailed Student’s t-test. 
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Chapter 3 
Mechanisms of albumin gene regulation downstream of Foxo1 
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Introduction 
 Although the mechanism by which insulin regulates albumin transcription 
has not been elucidated until the present study, the transcriptional regulation of 
the albumin gene has been extensively characterized:  Six distinct cis elements 
in the promoter region have been identified, as well as a handful of liver-enriched 
transcription factors that interact with the Alb promoter to activate albumin 
transcription, including hepatic nuclear factor 1α (Hnf-1α), D site binding protein 
(Dbp), and CCAAT/enhancer binding proteins (C/EBPs) (Lichtsteiner et al., 1987; 
Maire et al., 1989).  Of interest, C/EBPs are key regulators for cell differentiation 
and proliferation (Nerlov, 2008).  In liver, C/EBPs are essential for maintaining 
normal liver functions such as albumin production and bilirubin detoxification and 
clearance (Inoue et al., 2004; Y H Lee, 1997).  In addition, C/EBPs control the 
expression of key gluconeogenic and lipogenic enzymes, thus playing a 
significant role in regulating glucose and lipid metabolism in liver as well. 
 In the previous chapter, we have demonstrated that insulin signals directly 
on the liver to inhibit Foxo1, which functions as a transcriptional repressor of the 
albumin gene.  The specific mechanism of how Foxo1 functions as a repressor 
remains largely unknown.  Studies in C. elegans show that genes downregulated 
by DAF-16, the Foxo ortholog, are not directly bound by DAF-16, suggesting that 
Foxo represses gene expression by an indirect mechanism (Ramaswamy et al., 
2002; Tullet, 2014).  A recent study described a transcription factor called PQM-
1, which exhibits subcellular localization that is mutually antagonistic with that of 
DAF-16:  When DAF-16 is active and nuclear, PQM-1 is excluded from the 
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nucleus and subsequently its target genes are downregulated.  This provides a 
mechanism by which DAF-16 functions as a gene repressor (Tepper et al., 
2013).  To date, it is unclear whether an orthologous mechanism exists in 
mammals.  Nevertheless, recent studies in mammalian systems have provided 
evidence that Foxo1 could potentially repress gene expression by inducing the 
expression of other transcriptional repressor(s), or modulating the activity of other 
transcription factors.  
 In this chapter, we interrogated possible mechanisms by which Foxo1 
represses albumin gene expression.  We found that it is unlikely that Foxo1 
induces the expression of small heterodimer partner (Shp) or inhibitor of DNA 
binding protein 3 (Id3) to repress the albumin gene.  Interestingly, the 
transcriptional activity of C/EBPα was negatively correlated with Foxo1 activity.  
Furthermore, using chromatin immunoprecipitation (ChIP), we found that 
constitutive activation of Foxo1 was correlated with reduced C/EBPα binding to 
the albumin promoter.  
 
Results 
Shp and Id3 are unlikely the transcriptional repressors for albumin gene 
expression downstream of Foxo1 
 We first assessed the model in which Foxo1 functions as a repressor 
indirectly by inducing the expression of a transcriptional repressor, which in turn 
represses target genes.  Shp and Id3 are transcription repressors that have been 
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identified as putative targets of Foxo1 (Shin et al., 2012; Wei et al., 2011).  
Moreover, previous studies have suggested connections between these factors 
and albumin expression (Nakayama et al., 2006; Park et al., 2007).  To test 
whether Shp or Id3 represses albumin transcription downstream of Foxo1, we 
first measured their gene expression in our genetic models.  We found that for 
both Shp and Id3, gene expression was significantly induced in Akt-null livers 
where Foxo1 was constitutively active, and concomitant deletion of Foxo1 
completely reversed the gene induction (Figure 3.1A and B).  This observation is 
consistent with previous studies that Foxo1 directly induces Shp and Id3 
transcription.  In addition, the reciprocal expression pattern between albumin and 
Shp and Id3 is consistent with the model where Shp and/or Id3 repress albumin 
expression.  Nevertheless, the postprandial changes in Shp and Id3 gene 
expression in control animals are inconsistent with the model where Foxo1 
induces the expression of these repressors.  Specifically, upon feeding when 
Foxo1 becomes inhibited by insulin, Shp and Id3 expression should be 
downregulated according to the model.  Yet, our data shows that Shp expression 
was unchanged and Id3 expression was induced (Figure 3.1A and B), suggesting 
that Foxo1 might not be a physiologic regulator of Shp and Id3. 
 In addition, in Ir-null livers and streptozotocin (STZ)- induced diabetic 
livers, where Foxo1 was also constitutively active, we did not observe an 
induction of Shp or Id3 gene expression (Figure 3.1C-F).  This inconsistency 
suggests that the regulation of Shp and Id3 is more complex.  Therefore, it is 
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unlikely that Foxo1 represses albumin gene expression by inducing these 
transcription repressors. 
 
Gene expression of Cebpa was reduced in Akt-null livers 
 To investigate whether Foxo1 represses albumin expression by directly 
affecting the activity of a transcription factor, we then shifted our attention to the 
transcription factors known to regulate albumin expression.  Distinct cis-
regulatory sites have been identified in the Alb promoter, as well as the 
transcription factors bound at each site (Lichtsteiner et al., 1987; Maire et al., 
1989)(Figure 3.2A).  Notably, all factors identified are transcription activators.  
We decided to focus on examining C/EBPα, C/EBPβ, Dbp, and Hnf-1α because 
these transcription factors are liver-enriched and are associated with binding 
sites with the strongest activating potential (Maire et al., 1989).  
 We first measured the hepatic gene expression levels of these 
transcription factors.  Interestingly, we found that Cebpa showed a significant 
decrease in gene expression when Ir was specifically deleted in the liver (IRKO) 
in the fasted state and exhibited a trend of decrease that was not statistically 
significant in the fed state (Figure 3.2A), while the gene expression of Cebpb, 
Dbp, and Hnf1a was not affected (Figure 3.2B-E).  More importantly, concomitant 
deletion of Foxo1 (FoxoDKO) fully restored the decreased Cebpa expression to 
control levels (Figure 3.2B).  Similarly, liver-specific deletion of Akt1 and Akt2 
(AktDKO) had no effect on the expression levels of Cebpb, Dbp, and Hnf1a, but 
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led to a significant decrease in Cebpa gene expression (Figure 3.3A-D).  
Concomitant deletion of Foxo1 completely restored the decreased Cebpa 
expression to control levels in the fasted state, but only partially in the fed state 
(Figure 3.3A).  These results show that under certain conditions, Cebpa gene 
expression exhibits the same pattern as albumin, and both are negatively 
correlated with hepatic Foxo1 activity.  In addition, there seems to be other 
nutrient-dependent, Foxo1-independent pathways that regulate Cebpa 
expression. 
 We then asked whether the gene expression levels of these transcription 
factors were differentially regulated in Type 1 diabetic livers as well and whether 
Foxo1 activity also contributed to the transcription regulation.  To this end, we 
used STZ to induce diabetes in either control (GFP) or liver-specific Foxo1 
knockout mice (FoxoKO).  Surprisingly, STZ treatment did not have any effect on 
the gene expression of these transcription factors (Figure 3.4A-D), despite of the 
elevated Foxo1 activity.  Ablation of Foxo1 also showed no effect, suggesting 
that the transcriptional regulation of these genes was independent of Foxo1.   
 To test whether the decreased Cebpa gene expression correlated with a 
decrease in protein level, we measured the hepatic C/EBPα protein levels by 
Western blotting.  Interestingly, despite of the decreased mRNA levels, C/EBPα 
protein remained unchanged in IRKO and AktDKO livers, and concomitant 
deletion of Foxo1 in these models had no effect on the C/EBPα protein levels 
(Figure 3.5A and Figure 3.6A, respectively).  On the contrary, C/EBPβ protein 
levels were slightly increased in IRKO and AktDKO livers compared to control, 
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and concomitant ablation of Foxo1 in these models normalized the C/EBPβ 
protein to control levels (Figure 3.5B and Figure 3.6B, respectively). 
 
C/EBPα activity is negatively correlated with Foxo1 activity in liver 
 C/EBPα activates its own transcription in a positive feedback loop (Nerlov, 
2008).  Having observed a decreased Cebpa expression without detectable 
changes in C/EBPα protein levels, we hypothesized that C/EBPα activity was 
reduced in liver when Foxo1 was constitutively active.  To test this idea, we set 
out to measure expression levels of the C/EBPα target genes. 
11β-hydroxysteroid dehydrogenase type 1 (Hsd11b1) is a direct target 
gene of C/EBPα (Inoue et al., 2004; Williams et al., 2000).  Interestingly, we 
found that Hsd11b1 gene expression was significantly decreased in AktDKO 
livers, and concomitant deletion of Foxo1 fully rescued the expression to control 
levels (Figure 3.7A).  This observation is consistent with the hypothesis that 
C/EBPα activity is negatively correlated with Foxo1 activity in the liver.  To test 
whether C/EBPα activity was also reduced in Type 1 diabetic livers, we 
measured Hsd11b1 mRNA level in control and STZ-induced diabetic livers.  
Development of diabetes did not affect hepatic Hsd11b1 gene expression, 
suggesting that C/EBPα activity was unaffected in these livers.  In addition, 
deletion of Foxo1 specifically in the liver in either control or STZ-treated mice 
exhibited no effect on hepatic Hsd11b1 gene expression (Figure 3.7B).  These 
results suggest that C/EBPα activity was independent of Foxo1 activity in STZ-
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induced Type 1 diabetes model.  The discrepancy could be due to differences in 
experimental systems used (See Discussion). 
We also investigated whether the negative correlation between Foxo1 
activity and C/EBPα activity was a general phenomenon for all C/EBPα target 
genes or one specific for the regulation of Alb and Hsd11b1.  To this end, we first 
compiled a list of potential C/EBPα target genes by identifying the overlap 
between the C/EBPα ChIP-seq dataset and the list of genes differentially 
regulated in Cebpa knockout mice (Jakobsen et al.; Pedersen et al., 2007).  We 
reasoned that these genes would most likely represent the direct targets of 
C/EBPα as their expression levels are C/EBPα-dependent and they have 
C/EBPα bound near their transcription start sites.  We then measured the mRNA 
levels of these identified genes in GFP, AktDKO, and FoxoTKO livers.  Most of 
these genes exhibited differential expression in AktDKO livers compared to 
control.  Interestingly, concomitant deletion of Foxo1 (FoxoTKO) completely 
restored the altered gene expression back to control levels  (Figure 3.7C).  These 
results supported our hypothesis that it is a general mechanism where 
constitutive activation of Foxo1 is correlated with a decrease in C/EBPα activity.  
 
Constitutive activation of Foxo1 is correlated with decreased C/EBPα and 
C/EBPβ occupancy at the albumin promoter  
 Recent studies suggest that Foxo1 directly interacts with C/EBPα in 
adipocytes and neonatal liver to modulate C/EBPα activity (Qiao and Shao, 2006; 
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Sekine et al., 2007).  In addition, Foxo1 has been known to interact with 
transcription factors to interfere with their DNA binding (Deng et al., 2012; 
Dowell, 2003; Fan et al., 2009).  To test whether constitutive activation of Foxo1 
interferes with C/EBPα DNA binding at the albumin promoter, we performed 
chromatin immunoprecipitation (ChIP) of C/EBPα and C/EBPβ in control, 
AktDKO, and FoxoTKO livers.  Figure 3.8A shows the C/EBPβ binding peaks 
identified by ChIP-seq in wildtype mouse livers at the albumin promoter.  Since 
C/EBPα and C/EBPβ often bind to DNA as a heterodimer, the peaks were used 
to predict C/EBPα binding sites, which were confirmed by ChIP using an antibody 
directed against C/EBPα (Figure 3.8B).  Interestingly, C/EBPα and C/EBPβ 
occupancy at the albumin promoter was reduced in AktDKO livers compared to 
controls, and concomitant deletion of Foxo1 specifically in the liver reversed this 
decrease (Figure 3.8B and C).  This result indicates that Foxo1 activity was 
negatively correlated with C/EBPα and C/EBPβ binding to the albumin promoter, 
possibly by directly interacting with them and interfering with their DNA binding. 
 Next, we investigated whether C/EBPα binding to the albumin promoter 
was also decreased in diabetic livers.  To this end, we injected STZ to induce 
Type 1 diabetes in either control or FoxoKO mice and used ChIP to measure 
C/EBPα and C/EBPβ occupancy at the albumin promoter.  In STZ-induced 
diabetic livers, C/EBPα binding to the albumin promoter was decreased 
compared to control only at Site 2 (approximately 2.5kb upstream of the 
transcription start site, Figure 3.9A).  C/EBPβ binding to the albumin promoter, on 
the other hand, was increased in STZ-induced diabetic livers compared to control 
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(Figure 3.9B).  Importantly, ablation of Foxo1 restored all diabetes-induced 
changes in C/EBPα and C/EBPβ enrichment (Figure 3.9A and B).  Taken 
together, these results suggest that development of diabetes alters the binding of 
C/EBPα and C/EBPβ to the albumin promoters in a Foxo1-dependent manner. 
 
C/EBPα and C/EBPβ occupancy at the promoter of other Cebpa target genes 
 Since we observed decreased gene expression of other C/EBPα target 
genes such as Cebpa and Hsd11b1 (Figure 3.3A and Figure 3.7A, respectively), 
we hypothesized that this is due to decreased C/EBPα binding to the promoter of 
these genes as well, and C/EBPα occupancy at these sites would also be 
negatively correlated with Foxo1 activity.  To test this hypothesis, we first 
measured C/EBPα and C/EBPβ occupancy at the promoter of Cebpa (Figure 
3.10A) using ChIP.  C/EBPα showed a slightly decreased enrichment in AktDKO 
livers compared to control, although the difference did not reach statistical 
significance.  Importantly, concomitant deletion of Foxo1 restored the slight 
decrease back to control levels (Figure 3.10B).  C/EBPβ binding to the promoter 
of Cebpa was not different among GFP, AktDKO, and FoxoTKO livers (Figure 
3.10C).  Next, we examined the occupancy of C/EBPα and C/EBPβ at the Cebpa 
promoter in STZ-induced diabetic livers.  C/EBPα binding to the Cebpa promoter 
was not affected by the development of Type 1 diabetes (Figure 3.10D).  C/EBPβ 
occupancy, however, showed an increase in diabetic livers compared to controls.  
Furthermore, this increase was abrogated by deletion of Foxo1 specifically in the 
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liver (Figure 3.10 E), suggesting that increased binding of C/EBPβ to the Cebpa 
promoter was dependent on Foxo1 activity. 
 We also measured C/EBPα and C/EBPβ occupancy at the Hsd11b1 
promoter (Figure 3.11A).  Similar to what we observed at the Cebpa promoter, 
we found a slight, yet statistically insignificant decrease in C/EBPα occupancy at 
the Hsd11b1 promoter in AktDKO livers, which was restored when Foxo1 was 
concomitantly deleted (Figure 3.11B).  C/EBPβ binding to the Hsd11b1 was 
slightly increased in AktDKO livers.  However, this increase was independent of 
Foxo1 activity, as deletion of Foxo1 showed no effect (Figure 3.11C).  In STZ-
induced diabetic livers, C/EBPα binding to the Hsd11b1 promoter showed no 
difference when compared to controls, whereas C/EBPβ exhibited significantly 
increased enrichment, which was restored to control levels with the deletion of 
Foxo1 (Figure 3.11D and E), suggesting that the increased C/EBPβ binding to 
these sites was dependent on Foxo1 activity.  
 
Overexpressing C/EBPα in AktDKO livers to rescue the reduced albumin 
expression 
 Since we observed that the occupancy of C/EBPα at the albumin promoter 
directly correlated with albumin gene expression in GFP, AktDKO, and FoxoTKO 
livers, we hypothesized that the decreased C/EBPα DNA binding as a result of 
the constitutive activation of Foxo1 contributed to the decreased albumin 
expression.  To test this model, we overexpressed C/EBPα in AktDKO mice to 
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see if this could rescue the reduced albumin gene expression.  Using an adeno-
associated virus, we achieved an approximately 4-fold overexpression of Cebpa 
in liver (Figure 3.12B).  C/EBPα protein levels were also significantly increased 
compared to controls.  Notably, overexpressing C/EBPα did not affect hepatic 
C/EBPβ protein levels (Figure 3.12A).  We also observed increased gene 
expression of Hsd11b1 (Figure 3.12B), suggesting that C/EBPα overexpression 
led to increased hepatic C/EBPα activity at the Hsd11b1 promoter.  However, 
C/EBPα overexpression did not improve the circulating albumin level in AktDKO 
animals (Figure 3.12C).  To our surprise, albumin gene expression was further 
decreased in animals overexpressing C/EBPα (Figure 3.12D).   
 To understand this surprising result, we first assessed the effect of 
C/EBPα overexpression on restoring the reduced C/EBPα binding to DNA.  We 
found that the overexpression failed to increase C/EBPα occupancy at the 
promoters of Alb, Cebpa, and Hsd11b1 in AktDKO livers (Figure 3.13A).  This is 
likely the reason why C/EBPα overexpression failed to rescue the reduced 
albumin expression and production in AktDKO livers.  In addition, C/EBPβ 
occupancy at these sites was significantly decreased as a result of the C/EBPα 
overexpression (Figure 3.13B).  Since C/EBPβ is also a transcription activator of 
albumin, this might explain the further decrease in hepatic albumin mRNA levels.  
 
Discussion 
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 The Alb promoter does not contain a Foxo1 binding site, suggesting that it 
is unlikely for Foxo1 to repress albumin expression directly.  In this chapter, we 
investigated possible mechanisms by which Foxo1 represses albumin expression 
indirectly. 
 Shp and Id3 are putative transcription repressors downstream of Foxo1 
that might play a role in the regulation of albumin expression.  Specifically, Shp 
has been described to directly interact with C/EBPα and to decrease its 
transcriptional activity (Park et al., 2007).  Since C/EBPα activates albumin 
expression, we hypothesized that the induction of Shp by Foxo1 could potentially 
mediate the downregulation of albumin gene expression.  Id3 exhibits reciprocal 
expressions both in space and in time with albumin during chick liver 
development, consistent with it being an inducible repressor for albumin 
expression (Nakayama et al., 2006).  We found that the gene expression of Shp 
and Id3 were elevated in Akt-null livers, where Foxo1 activity was constitutively 
high, and concomitant deletion of Foxo1 reversed this induction (Figure 3.1A and 
B).  The reciprocal relationship between albumin expression and the expression 
of Shp and Id3 is consistent with the model where Shp and Id3 repress albumin 
transcription downstream of Foxo1.  However, the expression patterns of Shp 
and Id3 in control animals were inconsistent with the model where Foxo1 induces 
these transcription repressors during the fasting state (Figure 3.1 A-C), 
suggesting that Foxo1 might not be a physiologic regulator of these genes.  In 
addition, we did not observe the same relationship in the IRKO mice (Figure 
3.1C).  The discrepancy between the IRKO and AktDKO models also suggests 
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that regulation of Shp and Id3 is more complex and possibly depends on 
regulators other than Foxo1.  Therefore, repression mediated by Shp and Id3 is 
unlikely to be the unifying mechanism of how Foxo1 represses albumin gene 
expression.   
 Since a number of studies have demonstrated that Foxo1 interacts with a 
variety of transcription factors to modulate their activity (Christian, 2002; Deng et 
al., 2012; Dowell, 2003; Fan et al., 2009; Ramaswamy et al., 2002; Van der Vos 
and Coffer, 2008), we then turned our attention to transcription activators known 
to regulate albumin and assessed whether this is the mechanism by which Foxo1 
exerts its repressive effect on albumin gene expression.  Interestingly, under 
certain conditions, hepatic expression of Cebpa inversely correlated with Foxo1 
activity and consistent with albumin expression.  Specifically, in IRKO and 
AktDKO livers where Foxo1 was constitutively active, Cebpa exhibited decreased 
expression that was completely reversed by concomitant deletion of Foxo1 
especially in the fasted state.  Since C/EBPα regulates its own transcription, this 
observation suggests that C/EBPα activity exhibits a reciprocal relationship with 
Foxo1 activity in the liver, consistent with the model in which Foxo1 inhibits the 
activity of C/EBPα to mediate the repression of albumin expression.  In the fed 
state, however, inactivation of Foxo1 was not sufficient to restore the reduced 
Cebpa expression in Akt-null livers, suggesting that there are other nutrient-
dependent, Foxo1-independent pathways that regulate Cebpa expression.  
 To test the reciprocal relationship between C/EBPα and Foxo1, we 
measured the expression of Hsd11b1, a direct target gene of C/EBPα that is 
73 
involved in glucocorticoid synthesis in liver (Inoue et al., 2004; Williams et al., 
2000).  Consistent with the observed expression patterns of albumin and Cebpa, 
Hsd11b1 also exhibited significantly reduced expression in AktDKO livers that 
was reversed when Foxo1 was concomitantly deleted (Figure 3.7A), providing 
another piece of supporting evidence that C/EBPα activity was decreased when 
Foxo1 activity was constitutively high, and vice versa.  We then compiled a list of 
genes that are most likely the functional C/EBPα targets by examining the 
overlap between genes whose promoters are bound by C/EBPα (C/EBPα ChIP, 
(Jakobsen et al.)) and genes with differential expression when Cebpa is deleted 
(Cebpa knockout microarray, (Pedersen et al., 2007)).  We found that almost all 
C/EBPα target genes exhibited differential expression that was dependent on 
Foxo1 activity (Figure 3.7C), further validating the model that Foxo1 interferes 
with C/EBPα activity. 
 The decrease in C/EBPα activity in IRKO and AktDKO livers was not due 
to a loss of C/EBPα protein, as there was no detectable change in C/EBPα 
protein in IRKO and AktDKO livers, and concomitant deletion of Foxo1 in these 
livers exhibited no effect on C/EBPα protein levels (Figure 3.5A and Figure 3.6A).  
This suggests that decreased C/EBPα activity in IRKO and AktDKO livers was 
due to a decrease in the inherent transcription activating activity.  Interestingly, 
C/EBPβ protein was regulated differently as C/EBPα and was dependent on 
Foxo1 activity, as we observed a mild increase in C/EBPβ protein in both IRKO 
and AktDKO livers compared to control, and concomitant deletion of Foxo1 
completely reversed this increase (Figure 3.5B and Figure 3.6B).  These 
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observations highlight differential regulations of C/EBPα and C/EBPβ 
downstream of Foxo1:  C/EBPα seems to be regulated at the level of 
transcription, while C/EBPβ is regulated post-transcriptionally at the protein level 
either by translation or degradation.  
 Recent studies have revealed that Foxo1 can modulate gene expression 
independent of DNA-binding by associating with a variety of transcription factors 
(Christian, 2002; Deng et al., 2012; Dowell, 2003; Fan et al., 2009; Hirota et al., 
2008; Ramaswamy et al., 2002; Van der Vos and Coffer, 2008).  For instance, 
identified from a yeast two-hybrid screen, Foxo1 physically interacts with 
peroxisome proliferator-activated receptor γ (PPARγ) and disrupts PPARγ’s 
DNA-binding to antagonize its activity (Dowell, 2003).  Recently, Deng et al. 
found that Foxo1 inhibits SREBP-1c transcription by disrupting the assembly of 
the transcriptional complex at the Srebp1c promoter (Deng et al., 2012).  In 
addition, it has been shown that Foxo1 physically interacts with C/EBPα in 
adipocytes and neonatal liver (Qiao and Shao, 2006; Sekine et al., 2007).  
Collectively, these studies led us to speculate that Foxo1 may antagonize 
C/EBPα activity by directly interacting with C/EBPα and interfering with its DNA 
binding.  
 To assess C/EBPα binding to the albumin promoter, we performed 
chromatin immunoprecipitation in control, AktDKO, and FoxoTKO livers using an 
antibody targeted specifically at C/EBPα.  We found that C/EBPα occupancy at 
the albumin promoter was decreased in AktDKO livers compared to control, 
especially at the proximal promoter region (approximately 2.5kb upstream from 
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the transcription start site).  Moreover, concomitant deletion of Foxo1 restored 
the decreased occupancy to control level (Figure 3.8B).  This observation is 
consistent with our hypothesis that constitutively active Foxo1 may interfere with 
C/EBPα’s binding to DNA and thus lead to repression of the albumin gene.  We 
also observed a decrease in C/EBPβ occupancy at the albumin promoter (Figure 
3.8C).  It is possible that C/EBPβ binding to the albumin promoter was decreased 
as a result of disrupted C/EBPα binding, since these factors often bind to DNA as 
a heterodimer.  Interestingly, C/EBPα and C/EBPβ occupancy did not exhibit the 
same pattern at the distal promoter region (site 4, approximately 30kb upstream 
from the transcription start site), suggesting that at this site, C/EBPα and C/EBPβ 
interacted with the promoter as homodimers rather than a heterodimer: DNA-
binding of C/EBPα homodimer at this site was disrupted by Foxo1, whereas that 
of C/EBPβ homodimer was unaffected. 
We also examined the occupancy of C/EBPα and C/EBPβ at the 
promoters of Cebpa and Hsd11b1 in control, AktDKO, and FoxoTKO livers.  
Constitutively active Foxo1 in AktDKO livers was correlated to a slight, yet 
statistically insignificant, decrease in C/EBPα DNA binding to the promoters of 
these genes.  Nevertheless, concomitant deletion of Foxo1 still restored the slight 
decrease to control levels, suggesting that C/EBPα occupancy was dependent 
on Foxo1 (Figure 3.10B and Figure 3.11B).  On the contrary, C/EBPβ binding to 
these promoters was unaffected by Foxo1 activity level (Figure 3.10C and Figure 
3.11C).  Such disconnect between C/EBPα and C/EBPβ occupancy could be 
explained by the possibility that C/EBPα and C/EBPβ interacted with these sites 
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as homodimers exclusively, and Foxo1 only interfered with C/EBPα binding.  
Since gene expression for both Cebpa and Hsd11b1 was significantly decreased 
in AktDKO livers without a significant decrease in C/EBPα occupancy at the 
promoter, it is likely that other factors contributed to the repression of these 
genes as well. 
 To directly investigate the role of C/EBPα and test whether reduced 
C/EBPα occupancy is a major contributing factor for decreased albumin gene 
expression, we overexpressed C/EBPα in AktDKO livers in an attempt to rescue 
the decreased C/EBPα occupancy to see if that is sufficient to restore albumin 
production.  Using an adeno-associated virus, we achieved a 4-fold 
overexpression in Cebpa mRNA, and C/EBPα protein levels were significantly 
increased compared to controls (Figure 3.12A and B).  Hsd11b1 gene expression 
also significantly increased, suggesting that C/EBPα activity was elevated in 
these livers as a result of the overexpression (Figure 3.12B).  Importantly, 
C/EBPα overexpression exhibited no effect on C/EBPβ gene expression and 
protein levels in AktDKO livers (Figure 3.12A and B).  C/EBPα overexpression in 
AktDKO livers did not improve total serum protein concentration in these animals 
(Figure 3.12C).  Opposite to what we expected, C/EBPα overexpression actually 
exacerbated the already decreased albumin gene expression in AktDKO livers 
(Figure 3.12D).  Chromatin immunoprecipitation against C/EBPα revealed that 
despite of the increased protein levels, C/EBPα occupancy at the promoters of 
albumin, Cebpa, and Hsd11b1 did not increase as a result of the overexpression 
(Figure 3.13A).  Thus, it remains inconclusive whether decreased C/EBPα 
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binding to the albumin promoter is the major contributing factor for decreased 
albumin expression in AktDKO livers.  It is also interesting to note that even 
though C/EBPα occupancy at the Hsd11b1 promoter was not rescued in Cebpa-
overexpressing livers, Hsd11b1 expression was nonetheless elevated, 
suggesting that increased DNA-binding might not be the only mechanism 
C/EBPα has to activate gene expression.  Interestingly, C/EBPβ binding to the 
promoters of albumin, Cebpa, and Hsd11b1 was significantly decreased as a 
result of Cebpa overexpression (Figure 3.13B), possibly due to the distorted 
stoichiometric ratio of C/EBPα and C/EBPβ in these livers.  Since C/EBPβ is also 
a transcription activator of albumin expression, loss of C/EBPβ at the promoter of 
albumin could potentially contribute to the additional decrease in albumin 
expression in Cebpa-overexpressing AktDKO livers. 
 It is not clear why overexpressing Cebpa in AktDKO livers failed to restore 
the decreased C/EBPα occupancy at the albumin promoter.  One possibility is 
that C/EBPα binding sites become inaccessible when Akt is deleted in the liver.  
This could be caused by altered chromatin structure.  A recent study by Lee et al. 
demonstrates that Akt activity is correlated with histone acetylation level, which is 
known to regulate chromatin structure (Lee et al., 2014).  In Akt-null liver, histone 
acetylation level is likely low and the chromatin is likely more compact, which 
could contribute to reduced binding of C/EBPα.  Alternatively, it is possible that 
C/EBPα binding to the albumin promoter requires a cofactor that becomes 
downregulated in Akt-null liver.  The third possibility is that C/EBPα binding sites 
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could be occupied by another transcription factor that is upregulated in Akt-null 
liver.  The nature of these factors, however, is currently elusive.  
 As previous discussed, site 2 of the albumin promoter was most likely 
occupied by C/EBP α/β heterodimers, since the DNA binding of both factors was 
disrupted concomitantly (Figure 3.8B and C).  Instead of restoring the decreased 
occupancy of C/EBP α/β heterodimers at these sites, Cebpa overexpression 
increased the relative C/EBPα to C/EBPβ ratio in the cell and possibly led to a 
displacement of C/EBPβ, as suggested by the decrease in C/EBPβ occupancy 
(Figure 3.13A and B).  As a result, this site likely became occupied by C/EBP α/α 
homodimers.  Similarly, site 4 of the albumin promoter was possibly occupied by 
C/EBP α/α and C/EBP β/β homodimers, as only the occupancy of C/EBPα was 
dependent on Foxo1 activity but not that of C/EBPβ (Figure 3.8B and C).  We 
speculate that Cebpa overexpression displaced C/EBPβ, resulting in a loss of 
C/EBP β/β homodimers at this site.   
Sequential ChIP assay could be useful here to directly test the relative 
protein dimeric states at these sites.  Specifically, C/EBPα ChIP samples would 
be re-ChIPed by the C/EBPβ antibody.  By comparing the relative enrichment 
from first ChIP with that from the second ChIP, one may gain insights on the 
nature of the dimer occupying that particular site:  A site bound by C/EBP α/β 
heterodimer would exhibit preserved enrichment after re-ChIP with C/EBPβ 
antibody, whereas a site bound by C/EBP α/α homodimer would lose enrichment 
after C/EBPβ re-ChIP.  The reverse order - C/EBPβ ChIP followed by C/EBPα 
ChIP - could be used to test occupancy by C/EBP β/β homodimers.  This 
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experimental system would also be useful to assess the effect of over-expressing 
Cebpa on the C/EBP dimeric states.  
 We did not observe similar effects in the STZ-induced Type 1 diabetic 
model.  C/EBPα binding to the albumin promoter was only reduced at the 
proximal site, but not at the distal site as a result of diabetes (Figure 3.9A).  
Interestingly, STZ treatment led to a significant increase in C/EBPβ occupancy, 
and deletion of Foxo1 completely reversed this increase, suggesting that the 
enhanced C/EBPβ binding to the albumin promoter was dependent on Foxo1 
activity (Figure 3.9B).  Similar trend was also observed at the Cebpa and 
Hsd11b1 promoters, where STZ treatment did not affect C/EBPα binding, but 
constitutive activation of Foxo1 was correlated with enhanced C/EBPβ binding at 
these sites (Figure 3.10D and E, Figure 3.11D and E).  C/EBPβ exits as two 
isoforms: one activating and one inhibitory (Nerlov, 2007; 2008). The C/EBPβ 
antibody we used in ChIP experiments does not differentiate the two isoforms.  
Therefore, it is possible that the occupancy of the inhibitory C/EBPβ isoform was 
increased in STZ-treated livers, thus causing a decrease in albumin gene 
expression.  The specific C/EBPβ isoform recruited to the albumin promoter in 
this model requires further characterization.  
The discrepancy between the STZ-induced Type 1 diabetes model and 
the liver-specific genetic knockout model may be explained by either the genetic 
strain differences of the animals used in this study, or the drastic physiological 
differences between the two animal models.  Although liver-specific Ir knockout 
and liver-specific Akt1/Akt2 double-knockout animals develop peripheral insulin 
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resistance (Lu et al., 2012), the metabolic defect originated from the liver.  On the 
other hand, β-cell death following the STZ treatment leads to a systemic defect 
that affects all insulin-responsive organs, including liver, adipose, muscle, and 
brain.  As a result, the severity of the metabolic defects is much higher in the 
STZ-induced diabetes model, as indicated by their outrageously high blood 
glucose level as well as the significant loss of body mass.  It is thus difficult to de-
convolute the liver-specific mechanism that regulates albumin expression using 
the STZ-induced diabetes model.  
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Figure 3.1: Shp and Id3 are unlikely to be the transcriptional repressors 
downstream of Foxo1 to repress albumin expression. 
A,B. Hepatic gene expression level of small heterodimer partner (Shp, A) and 
inhibitor of DNA binding 3 (Id3, B) in GFP control (GFP), liver-specific Akt1/Akt2 
double-knockout (AktDKO), and liver-specific Akt1/Akt2/Foxo1 triple-knockout 
(FoxoTKO) animals that had been either fasted overnight or fasted overnight and 
refed for 4 hours.  n = 3-4; ns, not significant, **p<0.01 vs. GFP, and ***p<0.001 
vs. GFP by two-way ANOVA using Sidak post-test. 
C,D. Hepatic gene expression level of Shp (C) and Id3 (D) in GFP, liver-specific 
Ir knockout (IRKO), and liver-specific Ir/Foxo1 double-knockout (FoxoDKO) 
animals that had been either fasted overnight or fasted overnight and refed for 4 
hours.  n = 5-7; ns, not significant, *p<0.0.5 vs. GFP by two-way ANOVA using 
Sidak post-test. 
E,F. Hepatic gene expression level of Shp (E) and Id3 (F) in GFP and liver-
specific Foxo1 knockout (FoxoKO) animals 9 days post an intra-peritoneal 
injection of either buffer (Ctrl) or streptozotocin (STZ) at 200mg per kg body 
weight.  n = 5-7. 
All values are expressed as mean ± SEM. 
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Figure 3.2: Hepatic expression of transcription factors known to regulate 
albumin expression in liver-specific Ir knockout (IRKO) and liver-specific 
Ir/Foxo1 double-knockout (FoxoDKO) mice. 
A. Diagram of Alb promoter showing transcription factors that activate albumin 
expression and their respective binding sites.  Cebpa/b, CCAAT/enhancer 
binding protein a/b; Hnf1a, hepatic nuclear factor 1a; Nfy, nuclear factor Y; Dbp, 
D box binding protein; Nf1, neurofibromatosis factor 1. 
B-E. Hepatic gene expression of Cebpa (B), Cebpb (C), Dbp (D), and Hnf1a (E) 
in GFP control (GFP), IRKO, and FoxoDKO animals that had been either fasted 
overnight or fasted overnight and refed for 4 hours.  
All values are expressed as mean ± SEM.  n = 5-9; ns, not significant; *p<0.05 
vs. GFP by two-way ANOVA using Sidak post-test. 
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Figure 3.3: Hepatic expression of transcription factors known to regulate 
albumin expression in liver-specific Akt1/Akt2 double-knockout (AktDKO) 
and liver-specific Akt1/Akt2/Foxo1 triple-knockout (FoxoTKO) mice. 
Hepatic gene expression of CCAAT/enhancer binding protein a (Cebpa, A), 
Cebpb (B), D box binding protein (Dbp, C), and hepatic nuclear factor 1a (Hnf1a, 
D) in GFP control (GFP), AktDKO, and FoxoTKO animals that had been either 
fasted overnight or fasted overnight and refed for 4 hours.  
Cebpa mRNA
Fasted Refed
0.0
0.5
1.0
1.5
2.0
ns
Fo
ld
 C
ha
ng
e
***
**
***
Cebpb mRNA
Fasted Refed
0.0
0.5
1.0
1.5
2.0
Fo
ld
 C
ha
ng
e
GFP
AktDKO
FoxoTKO
Dbp mRNA
Fasted Refed
0
2
4
6
Fo
ld
 C
ha
ng
e
Hnf1a mRNA
Fasted Refed
0.0
0.5
1.0
1.5
2.0
2.5
Fo
ld
 C
ha
ng
e
A B
C D
86 
All values are expressed as mean ± SEM.  n = 3-4; ns, not significant, **p<0.01 
vs. GFP, and ***p<0.001 vs. GFP by two-way ANOVA using Sidak post-test. 
87 
 
 
Figure 3.4: Hepatic expression of transcription factors known to regulate 
albumin expression in Type 1 diabetic livers. 
Hepatic gene expression of CCAAT/enhancer binding protein a (Cebpa, A), 
Cebpb (B), D box binding protein (Dbp, C), and hepatic nuclear factor 1a (Hnf1a, 
D) in GFP control (GFP) and liver-specific Foxo1 knockout (FoxoKO) animals 9 
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days post an intra-peritoneal injection of either buffer (Ctrl) or streptozotocin 
(STZ) at 200mg per kg body weight. 
All values are expressed as mean ± SEM. 
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Figure 3.5: Hepatic C/EBPα and C/EBPβ protein levels in liver-specific Ir 
knockout (IRKO) and liver-specific Ir/Foxo1 double-knockout (FoxoDKO) 
mice. 
Western blots for C/EBPα (A), C/EBPβ (B), and actin in liver homogenates of 
GFP control (GFP), IRKO, and FoxoDKO animals. 
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Figure 3.6: Hepatic C/EBPα and C/EBPβ protein levels in liver-specific 
Akt1/Akt2 double-knockout (AktDKO) and liver-specific Akt1/Akt2/Foxo1 
triple-knockout (FoxoTKO) mice. 
Western blots for C/EBPα (A), C/EBPβ (B), and actin in liver homogenates of 
GFP control (GFP), AktDKO, and FoxoTKO animals. 
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Figure 3.7: C/EBPα target genes exhibit differential expression in Akt-null 
livers that is restored by additional deletion of Foxo1.  
A. Hepatic Hsd11b1 mRNA level in GFP control (GFP), liver-specific Akt1/Akt2 
double knockout (AktDKO), and liver-specific Akt1/Akt2/Foxo1 triple-knockout 
(FoxoTKO) animals.  n = 3-4; ns, not significant, and ***p<0.001 vs. GFP by one-
way ANOVA using Sidak post-test. 
B. Hepatic Hsd11b1 mRNA in GFP and liver-specific Foxo1 knockout (FoxoKO) 
animals 9 days post an intra-peritoneal injection of either buffer (Ctrl) or 
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streptozotocin (STZ) at 200mg per kg body weight.  n = 5-7; ns, not significant by 
two-way ANOVA using Sidak post-test. 
C. Hepatic mRNA levels of other putative target genes of C/EBPα in GFP, 
AktDKO, and FoxoTKO animals.  Apob, apolipoprotein B; Apoc3, apolipoprotein 
C-III; Saa4, serum amyloid A4; Cps1, carbamoyl-phosphate synthetase 1; Alas2, 
aminolevulinic acid synthase 2; Cd1d1, CD1d1 antigen; Mrap, melanocortin 2 
receptor accessory protein; Prlr, prolactin receptor; Fgf1, fibroblast growth factor 
1; Smpd3, sphingomyelin phosphodiesterase 3; Fgfr2, fibroblast growth factor 
receptor 2; Sulf2, sulfatase 2; Tgfbr2, transforming growth factor, beta receptor II.  
n = 3-4; ns, not significant, *p<0.05 vs. GFP, **p<0.01 vs. GFP, and ***p<0.001 
vs. GFP by two-way ANOVA using Sidak post-test. 
All values are expressed as mean ± SEM. 
93 
 
 
Figure 3.8: C/EBPα and C/EBPβ binding to the albumin promoter negatively 
correlates with hepatic Foxo1 activity.  
A. ChIP-seq profile for C/EBPβ at the albumin promoter.  C/EBPβ binding sites 
selected for analyzing C/EBPα and C/EBPβ enrichment are indicated.   
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B, C. Hepatic enrichment of C/EBPα (A) and C/EBPβ (B) at indicated sites of the 
albumin promoter in GFP control (GFP), liver-specific Akt1/Akt2 double-knockout 
(AktDKO), and liver-specific Akt1/Akt2/Foxo1 triple-knockout (FoxoTKO) animals.  
Ins serves as a negative control site not bound by C/EBPα. 
All values are expressed as mean ± SEM.  n = 3-4; **p<0.01 vs. GFP by one-way 
ANOVA using Sidak post-test. 
95 
 
 
Figure 3.9: C/EBPα and C/EBPβ binding to the albumin promoter in diabetic 
liver. 
Hepatic enrichment of C/EBPα (A) and C/EBPβ (B) at indicated sites (See Figure 
3.10A) of the albumin promoter in GFP control (GFP) and liver-specific Foxo1 
knockout (FoxoKO) animals 9 days post an intra-peritoneal injection of either 
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buffer (Ctrl) or streptozotocin (STZ) at 200mg per kg body weight.  Ins and Arbp 
serve as negative control sites not bound by C/EBPα. 
All values are expressed as mean ± SEM.  n = 3; **p<0.01 vs. GFP+Ctrl, and 
***p<0.001 vs. GFP+Ctrl by two-way ANOVA using Sidak post-test.  
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Figure 3.10: C/EBPα and C/EBPβ binding to the Cebpa promoter. 
A. ChIP-seq profile for C/EBPβ at the Cebpa promoter.  C/EBPβ binding sites 
selected for analyzing C/EBPα and C/EBPβ enrichment are indicated. 
B,C. Hepatic enrichment of C/EBPα (B) and C/EBPβ (C) at indicated sites of the 
Cebpa promoter in GFP control (GFP), liver-specific Akt1/Akt2 double-knockout 
(AktDKO), and liver-specific Akt1/Akt2/Foxo1 triple-knockout (FoxoTKO) animals.  
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D,E. Hepatic enrichment of C/EBPα (C) and C/EBPβ (D) at indicated sites of the 
Cebpa promoter in GFP and liver-specific Foxo1 knockout (FoxoKO) animals 9 
days post an intra-peritoneal injection of either buffer (Ctrl) or streptozotocin 
(STZ) at 200mg per kg body weight.  
All values are expressed as mean ± SEM. n = 3-4; ***p<0.001 vs. GFP+Ctrl by 
two-way ANOVA using Sidak post-test. 
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Figure 3.11: C/EBPα and C/EBPβ binding to the Hsd11b1 promoter. 
A. ChIP-seq profile for C/EBPβ at the Hsd11b1 promoter.  C/EBPβ binding sites 
selected for analyzing C/EBPα and C/EBPβ enrichment are indicated. 
B,C. Hepatic enrichment of C/EBPα (B) and C/EBPβ (C) at the indicated sites of 
the Hsd11b1 promoter in GFP control (GFP), liver-specific Akt1/Akt2 double-
knockout (AktDKO), and liver-specific Akt1/Akt2/Foxo1 triple-knockout 
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(FoxoTKO) animals.  n = 3; N.A., not available, and *p<0.05 vs. GFP by two-way 
ANOVA using Sidak post-test. 
D,E. Hepatic enrichment of C/EBPα (D) and C/EBPβ (E) at indicated sites of the 
Hsd11b1 promoter in GFP and liver-specific Foxo1 knockout (FoxoKO) animals 9 
days post an intra-peritoneal injection of either buffer (Ctrl) or streptozotocin 
(STZ) at 200mg per kg body weight.  n = 3; N.A., not available, and ***p<0.001 
vs. GFP+Ctrl by two-way ANOVA using Sidak post-test. 
All values are expressed as mean ± SEM. 
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Figure 3.12: Overexpression of Cebpa in liver-specific Akt1/Akt2 double-
knockout (AktDKO) animals fails to rescue the reduced albumin 
production. 
A. Western blots for C/EBPα and C/EBPβ in liver homogenates of AktDKO 
animals that either do (AAV-C/EBPα) or do not (AAV-GFP) overexpress Cebpa. 
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B-D. Hepatic gene expression of Cebpa, Cebpb, and Hsd11b1 (B), serum protein 
concentration (C), and hepatic albumin mRNA level (D) in AktDKO animals that 
either do or do not overexpress Cebpa.   
All values are expressed as mean ± SEM.  n = 2-3; ns, not significant, *p<0.05 
vs. AktDKO+AAV-GFP, **p<0.01 vs. AktDKO+AAV-GFP, and ***p<0.001 vs. 
AktDKO+AAV-GFP by two-tailed Student’s t-test. 
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Figure 3.13: Overexpression of Cebpa in liver-specific Akt1/Akt2 double-
knockout (AktDKO) animals fails to rescue the reduced C/EBPα binding to 
the albumin promoter and further decreases C/EBPβ occupancy. 
Hepatic enrichment of C/EBPα (A) and C/EBPβ (B) at indicated sites of the Alb, 
Cebpa, and Hsd11b1 promoters (See Figure 3.9A, Figure 3.11A, and Figure 
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3.12A) in AktDKO animals that either do (AktDKO+AAV-C/EBPα) or do not 
(AktDKO+AAV-GFP) overexpress Cebpa.  Ins serves as a negative control site 
not bound by C/EBPα. 
All values are expressed as mean ± SD.  n = 2; N.A., not available, *p<0.05 vs. 
AktDKO+AAV-GFP, **p<0.01 vs. AktDKO+AAV-GFP 
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Insulin stimulates albumin transcription by inhibiting Foxo1  
 The effects of insulin on carbohydrate and lipid metabolism have been 
extensively characterized, but how insulin regulates protein metabolism remains 
largely unknown (Kimball et al., 1994; Tessari et al., 2011).  Although it has been 
almost 30 years since it was first demonstrated that insulin controls serum 
albumin production in liver by stimulating albumin transcription (Lloyd et al., 
1987), the detailed pathway has not been elucidated until the present study.  
Using liver-specific knockout models, we found that insulin signals directly on the 
liver through Akt to phosphorylate and inhibit Foxo1, which functions as a 
transcription repressor of the albumin gene.  We also found that chronic 
activation of hepatic Foxo1 in Type 1 diabetic subjects is causal for the 
hypoalbuminemia phenotype in these individuals.   
We speculate that this regulatory mechanism of insulin was evolved to 
limit nonessential biosynthesis during metabolic stress.  Albumin mRNA and 
protein have a long half-life and therefore do not change with normal fasting and 
feeding, but decrease during diabetes and prolonged starvation.  Under these 
conditions, nutrients for energy generation to sustain survival become extremely 
limited.  Since that albumin is synthesized at a high rate (12-25 grams per day in 
a young healthy adult) (Fanali et al., 2012), it is essential to efficiently turn off its 
production to preserve the limited amino acids during an extended fast, and the 
most effective way to achieve this would be to reduce the level of mRNA 
message.  
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Foxo1 is a transcriptional repressor of the Alb gene 
 There still remains considerable uncertainty about the mechanism by 
which Foxo1 functions as a repressor of the albumin gene.  Previous works have 
shown that the DNA-binding domain of Foxo is not required for Foxo to mediate 
gene repression, suggesting an indirect mechanism (Murphy et al., 2003; 
Schuster et al., 2010; Tepper et al., 2013).  A recent study in C. elegans 
described PQM-1 as a transcription activator that exhibits reciprocal cellular 
localization as Foxo1, thereby presenting a possible mechanism in which Foxo1 
activation leads to the nuclear exclusion of PQM-1 and subsequent gene 
downregulation (Tepper et al., 2013).  However, it is not clear whether an 
orthologous mechanism exists in mammalian systems.  Here, we propose three 
indirect mechanisms by which Foxo1 represses albumin gene expression: 1) by 
modulating the activity of another transcription factor via direct protein-protein 
interaction; 2) by inducing the expression of a transcriptional repressor; and 3) by 
mediating a metabolic change in the cell. 
 
Foxo1 as a repressor via direct protein-protein interaction 
 Previous studies have extensively characterized the transcriptional 
regulation of Alb and identified C/EBPα, C/EBPβ, Hnf-1α, and Dbp as several 
liver-enriched transcription factors that stimulate albumin gene expression 
(Lichtsteiner et al., 1987; Maire et al., 1989).  Our results show that Foxo1 activity 
is inversely correlated with the occupancy level of C/EBPα at the albumin 
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promoter.  Although we did not perform co-immunoprecipitation experiments to 
directly demonstrate that Foxo1 and C/EBPα physically interact with each other, 
previous experimental data from other studies in adipocytes and neonatal liver 
suggests that such interaction is very likely (Qiao and Shao, 2006; Sekine et al., 
2007). Given these data, we speculate that in the absence of insulin signaling, 
Foxo1 is nuclear and directly binds to C/EBPα; the interaction between C/EBPα 
and Foxo1 decreases C/EBPα binding to the albumin promoter, and thus 
downregulates albumin gene expression.  This model is further supported by 
other examples in literature where Foxo1 directly interacts with transcription 
factors to inhibit their DNA binding (Christian, 2002; Deng et al., 2012; Dowell, 
2003; Fan et al., 2009; Hirota et al., 2008; Ramaswamy et al., 2002; Van der Vos 
and Coffer, 2008).  Taken together, this could indeed be the mechanism by 
which Foxo1 acts as a repressor for albumin transcription.  It is important to note, 
however, that in the present study, we only examined how Foxo1 influences the 
DNA binding of C/EBPs.  It is entirely possible that in addition to these 
transcription factors, Foxo1 also binds to and interferes with other transcription 
activators that regulate albumin gene expression.  
 
Foxo1 as a repressor by inducing an intermediate repressor 
 In addition to regulating the transcription of insulin-responsive genes such 
as gluconeogenic enzymes, Foxo1 also regulates the expression of other 
transcription factors.  Thus, it is possible that Foxo1 represses gene expression 
by inducing the expression of an intermediate repressor.  Although no repressor 
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for albumin gene expression has been described to date, we found that Shp and 
Id3, repressors induced by Foxo1, may play a role in albumin gene regulation 
(Nakayama et al., 2006; Shin et al., 2012).  We tested whether Shp and Id3 could 
mediate albumin gene repression downstream of Foxo1 in our models and found 
contradictory results.  Specifically, while Shp and Id3 were induced in Akt-
deficient livers in a Foxo1-dependent manner, this pattern was not observed in 
IR-deficient livers.  This inconsistency suggests that regulation of Shp and Id3 is 
more complex and might involve factors other than Foxo1.  Since albumin gene 
expression was decreased in both Akt-deficient and IR-deficient livers, it is 
unlikely that induction of Shp and Id3 was the mediator for albumin gene 
repression downstream of Foxo1.  Additional studies might be necessary to 
determine whether other transcription repressors act downstream of Foxo1 to 
repress albumin expression.  
 
Foxo1 as a repressor by mediating metabolic changes 
 Albumin expression in STZ-induced Type 1 diabetic mice was also 
decreased, and liver-specific deletion of Foxo1 was sufficient to restore albumin 
expression to control levels in these mice.  However, the mechanism by which 
Foxo1 represses albumin gene expression in this model was not immediately 
clear.  Despite of the high Foxo1 activity, C/EBPα binding to the Alb promoter 
was unaffected, indicating that the reduction in albumin expression was not 
caused by decreased C/EBPα activity at the promoter.  The discrepancy between 
this model and the liver-specific knockout models could be due to genetic strain 
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variation: we used mice of mixed background for the STZ studies, and our liver-
specific knockout model mice were of pure Bl6 background.  In addition, the 
discrepancy is most likely caused by different pathogenesis of diabetes in these 
two models.  STZ injection leads to β-cell death and therefore completely 
obliterates whole-body insulin signaling.  In the liver-specific knockout models, on 
the other hand, disruption of insulin signaling originates specifically in the liver, 
and insulin resistance is subsequently developed in peripheral tissues.  STZ-
induced Type 1 diabetes represents a more severe and systemic disruption of 
metabolic homeostasis, thus it is challenging to determine the liver-specific 
mechanism of how Foxo1 represses albumin expression using this model.  
 Regardless, there must be a mechanism that explains our observation that 
albumin expression was inversely correlated with Foxo1 activity in STZ-induced 
Type 1 diabetic liver.  One possibility is that the normalization of albumin 
transcription is downstream of the metabolic effects of inhibiting Foxo1.  
Numerous studies have shown that antagonizing or reducing hepatic Foxo1 in 
insulin resistant mice can significantly improve glucose tolerance and insulin 
action (Altomonte et al., 2003; Dong et al., 2008; Lu et al., 2012; Matsumoto, 
2006; Matsumoto et al., 2007; Samuel et al.).  For instance, earlier work from our 
laboratory shows that concomitant liver-specific deletion of Foxo1 normalizes the 
metabolic defects observed in mice with Akt-deficient liver (Lu et al., 2012).  We 
speculate that defective albumin gene expression in STZ-induced diabetic liver 
may be normalized as a result of the improved metabolic homeostasis.   
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Foxo1 inhibition normalizes glucose utilization in the liver, possibly by 
increasing the expression of glucose kinase (Gck) and/or decreasing the 
expression of pyruvate dehydrogenase kinase 4 (Pdk4) (O-Sullivan et al., 2015).  
Gck catalyzes the first step of the glycolytic pathway, where dietary glucose 
becomes phosphorylated and retained inside the hepatocytes.  Pdk4 
phosphorylates and inhibits pyruvate dehydrogenase (Pdh), which converts 
pyruvate to acetyl-CoA, a key enzymatic step to shuttle carbohydrate into the 
citric acid cycle for lipid synthesis or energy generation.  Therefore, inhibition of 
Foxo1 would lead to increased flux through the glycolytic pathway and the citric 
acid cycle, generating more energy and/or acetyl-coA in the cell.  Increased 
energy charge in liver would alter activities of energy-sensing pathways such as 
AMP-activated protein kinase (AMPK) and cAMP responsive element binding 
protein (CREB), leading to transcriptional changes.  In addition to energy 
generation and lipid synthesis, acetyl-CoA is also used to modify lysine residues 
of proteins, including transcription factors and histones.  Acetylation of 
transcription factors has been shown to regulate their activity (Park et al., 2015).  
Histone acetylation is sensitive to cellular metabolism and plays an important role 
in gene regulation as well (Grunstein, 1997; Wellen et al., 2009).  It is thus 
conceivable that either increased ATP or higher level of acetyl-CoA in 
hepatocytes could induce albumin gene expression.   
 
Hepatic autophagy contributes to serum albumin production  
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 Autophagy is an important quality control process that degrades and 
recycles damaged cellular proteins and organelles.  In addition to its 
housekeeping role, autophagy also maintains metabolic homeostasis in various 
tissues and serves as a significant source of biosynthetic substrates and energy 
during metabolic stress (Kim and Lee, 2014; Rabinowitz and White, 2010; 
Yamada and Singh, 2012).  In liver, insulin signaling turns off autophagy by 
activating mTORC1, which inhibits autophagy (Kim and Lee, 2014).  Autophagy 
also modulates insulin action: suppressing autophagy impairs insulin signaling 
and inducing hepatic autophagy can increase insulin sensitivity in the liver (Yang 
et al., 2010).  To our surprise, we found that hepatic autophagy, a catabolic 
process, positively contributes to serum albumin biosynthesis and secretion.  
Disrupting hepatic autophagy leads to a decrease in serum albumin level in 
overnight-fasted animals.  In addition, autophagy can maintain some level of 
albumin production in livers with impaired Akt and mTORC1 activity.  
 Contribution of autophagy on serum albumin production occurs at a post 
transcription site.  We speculate that autophagy supports albumin protein 
translation by supplying amino acids and/or energy generated from autophagic 
degradation.  In addition, recent data suggests that co-localization of 
autophagosomes and mTORC1 facilitates the synthesis and secretion of proteins 
(Narita et al., 2011).  Based on this observation, it is possible that hepatic 
autophagy also contributes to serum albumin production by augmenting its 
secretion.  A pulse-chase experiment would be helpful to directly address 
whether autophagy contributes to albumin secretion.  Incorporation of puromycin, 
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an aminoacylated-tRNA analog, into nascent peptide chain is a method 
alternative to radioactive amino acid labeling to study protein synthesis (Schmidt 
et al., 2009).  Present at very low concentration (10µg/ml), puromycin does not 
inhibit protein synthesis and its incorporation is conveniently detected by 
immunoblotting.  To measure albumin secretion in AktDKO and Atg5TKO 
hepatocytes, I will incubate the cells with puromycin for 10 minutes, followed by a 
90-minute chase.  At each time point within the chase period, albumin in the 
culture media will be immunoprecipiated, and levels of puromycin incorporation 
into albumin will be analyzed by western blot.  If the appearance rate of 
puromycin-containing albumin in the media is decreased in Atg5TKO 
hepatocytes, then it suggests autophagy augments the secretory capacity of 
hepatocytes to contribute to protein production. 
 
Serum albumin production is intact in Type 2 diabetes 
 Using our liver-specific knockout models, we found that albumin 
transcription is significantly reduced when insulin signaling is disrupted in the 
liver.  It is important to recognize that in these models, insulin signaling is 
completely absent and is therefore not fully representative of Type 2 diabetic 
livers, where insulin action is impaired.  To assess how albumin transcription is 
affected in insulin resistant livers, we measured serum albumin level and hepatic 
Alb mRNA in leptin-deficient (ob/ob) mice, a common model for obesity and Type 
2 diabetes.  We found that unlike what we observed in liver-specific knockout 
models, serum albumin transcription and secretion are completely normal in 
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ob/ob mice.  Consistent with our observation, an earlier study also showed that 
serum albumin production is normal in Type 2 diabetic patients (Tessari et al., 
2006b).  Taken together, we conclude that regulation of serum albumin 
production by insulin is intact in Type 2 diabetes despite of the hepatic insulin 
resistance.  
 Type 2 diabetic patients exhibit the “classic triad” of hyperinsunlinemia, 
hyperglycemia, and hypertriglyceridemia.  However, this triad of metabolic 
defects breaks down when insulin signaling is disrupted at the insulin receptor 
level (Michael et al., 2000).  This apparent paradox is explained by the dual 
action of insulin in the liver: insulin suppresses glucose production by 
phosphorylating and inhibition Foxo1, which induce the expression of key 
gluconeogenic enzymes; insulin also activates hepatic lipogenesis to increase 
lipid synthesis and secretion.  To explain the simultaneous elevation of glucose 
and lipid production in liver in Type 2 diabetes, Brown and Goldstein suggested a 
model of “selective insulin resistance”, where insulin is unable to inhibit Foxo1 to 
suppress gluconeogenesis but continues to sustain lipogenesis (Brown and 
Goldstein, 2008).  However, if this model is correct, Foxo1 should remain active 
in leptin-deficient mice, and should thus repress albumin expression.  Since we 
found that albumin expression in these animals was normal, our data does not 
support the hepatic selective insulin resistance model.   
 In an alternative view, Otero and colleagues suggested that the primary 
phenotypic driver for Type 2 diabetes is altered substrate delivery to the liver and 
hepatic nutrient handling, and not impaired insulin action per se 
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(Otero et al., 2014).  This model is supported by experimental evidence indicating 
that failure of insulin to suppress gluconeogenesis in liver is driven by substrate 
uptake and not gene expression (Catchpole et al., 2007; Edgerton et al., 2009; 
Ramnanan et al., 2010; Shawn C Burgess, 2007).  In this model, insulin-
mediated Foxo1 inhibition is likely intact in Type 2 diabetes, which is consistent 
with our observation that albumin expression is normal in ob/ob animals. 
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Animals 
All experiments were performed in male mice that were 10-12 weeks of 
age.  The IrloxP/loxP, IrloxP/loxP ; Foxo1loxP/loxP, Akt1loxP/loxP ; Akt2loxP/loxP, Akt1loxP/loxP ; 
Akt2loxP/loxP ; Foxo1loxP/loxP, and Foxo1loxP/loxP mice have been described previously 
(Leavens and Birnbaum, 2011; Matsumoto, 2006; Michael et al., 2000).  To 
generate liver-specific knockouts, an adeno-associated virus expressing either 
GFP or Cre recombinase driven by the promoter of liver-specific gene thyroxine 
binding globulin (TBG) was injected into the above mice at 8-10 weeks of age (1 
x 1011 genomic copies per mouse).  Experiments were performed 2 weeks post 
virus injection.  For fasting-refeeding experiments, mice were deprived of food for 
16 hours (4pm to 9am).  The fasted group was sacrificed at 9am, and the refed 
group was fed ad libitum for 4 hours with normal chow (Laboratory Rodent Diet, 
Cat. 5001) before sacrifice.  All animal experiments were reviewed and approved 
by the University of Pennsylvania Institutional Animal Care and Use Committee 
in accordance with NIH guidelines. 
 
Liver lysates/nuclear extract extraction and Western blotting  
Post sacrifice, livers were dissected, freeze-clamped, and stored at -80°C.  
Whole cell lysates were prepared by homogenizing frozen liver samples in RIPA 
buffer (150 mM NaCl, 50 mM Tris, pH 7.6, 1% Triton X-100, 0.5% sodium 
deoxycholate, 0.1% SDS, supplemented with protease and phosphatase 
inhibitors).  To detect Foxo1, liver nuclear extracts were prepared using the NE-
118 
PER Nuclear and Cytoplasmic Extraction Reagents (Thermo Scientific, Cat. 
78833).  Cleared lysates and nuclear extracts were resolved by SDS-PAGE (10-
12% acrylamide gel, constant voltage of 100V), transferred onto nitrocellulose 
membranes, probed with various antibodies (IR, Cell Signaling, Cat. 3025S; 
Foxo1, Cell Signaling, Cat. 9454S; Akt1, Cell Signaling, Cat. 2967; Akt2, Cell 
Signaling, Cat. 2964S; Actin, Abcam, Cat. ab6276) and visualized with either 
IRDye secondary antibodies (LI-COR Biosciences, Cat. 926-32213 and 926-
68022) or ECL Western blotting detection reagents (Thermo Scientific, Cat. 
32106). 
 
Primary hepatocytes isolation and in vitro albumin secretion assay  
Primary hepatocytes were isolated as previously described (Miller et al., 
2013).  Cells were plated on collagen-treated plates in DMEM supplemented with 
10% fetal bovine serum.  After a 2-3 hr attachment period, cells were washed 
twice with PBS and incubated in serum-free Krebs-Ringer Bicarbonate Buffer 
(Sigma-Aldrich, Cat. K4002) supplemented with 20mM HEPES, pH 7.4 and 0.5% 
BSA for 2 hours.  Media was collected and hemoglobin (Sigma Aldrich, Cat. 
H2625) was added as a carrier protein (final concentration of 0.1%, w/v).  For 
trichloroacetic acid (TCA) precipitation, 1 volume of 100% TCA (w/v) was added 
to 4 volume of sample to precipitate total protein.  The protein pellet was washed 
twice in ice-cold acetone, dried, and re-suspended in Laemmli sample buffer 
(volume adjusted based on cellular protein content).  Albumin in the samples was 
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then measured by Western blotting (Anti-Alb, Nordic Immunology, Cat. 
RAM/Alb/7s). 
 
mRNA isolation and real-time PCR  
Total RNA was isolated from frozen livers or primary hepatocytes using 
the Nucleospin RNA Mini Kit (Clontech Labs, Cat. 740955.250).  cDNA was 
synthesized using M-MLV reverse transcriptase (New England Biolabs, Cat. 
M0253S).  Liver cDNA from transgenic mice expressing a constitutively active 
Foxo1 was a generous gift from Dr. Terry G. Unterman (University of Illinois at 
Chicago College of Medicine) (Deng et al., 2012).  The relative expression of 
genes of interest was quantified by real-time PCR using the SYBR Green Dye-
based assay.  
 
Serum albumin measurement  
Blood samples were collected post sacrifice by cardiac puncture.  After 
allowing the blood to clot, the samples were centrifuged to separate the sera.  
Albumin levels were measured using the BCG Albumin Assay Kit (Sigma Aldrich, 
Cat. MAK124). 
 
Streptozotocin-induced Type 1 diabetes  
At 8 to 10 weeks of age, Foxo1loxP/loxP mice received a retro-orbital 
injection of adeno-associated virus encoding either GFP or Cre recombinase at 1 
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x 1011 genomic copies per mouse.  5 days after virus injection, mice received an 
intra-peritoneal injection of either control buffer (0.1 M citrate, pH 4.5) or 
streptozotocin (EMD Chemicals, Cat. 572201) at 200 mg per kg body weight.  
Mice were sacrificed 2 weeks after virus injection (9 days after STZ injection).   
 
Chromatin immunoprecipitation (ChIP) assay 
Liver chromatin was prepared as previously described (Tuteja et al., 
2008).  Immunoprecipitations were performed using anti-C/EBPα (Santa Cruz, 
Cat. sc-61, 10µg per IP).  Real-time PCR oligos used to measure occupancy are 
listed below. 
 
Statistical analysis  
All values are expressed as mean ± SEM.  Two-way ANOVA with 
Bonferroni posttest was used if multiple conditions were involved when 
comparing different genotypes.  Two-tailed, unpaired Student’s t-test was used 
when only two groups of data were concerned. 
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Real-time PCR oligos used to measure C/EBPα occupancy 
Alb-1f CGCAAGGGATTTAGTCAAACAAC 
Alb-1r AACCATACTTACCTCGCATTTCA 
Alb-2f TCCCAGACCCATCAATTGTG 
Alb-2r TCCTGGCTCTTAGATTGCTCA 
Alb-3f AGCTAACCTTCTGTCCTAGTGG 
Alb-3r TGAACTCTGACTCACGATGGA 
Alb-4f ACAGAGGGTTGGATGGACAC 
Alb-4r CCTCATTACCTTTGTGCACCA 
Cebpa-1f AGGAGTCAGTGGGCGTTG 
Cebpa-1r GTCTTAGAGCCCGCCTTCTC 
Cebpa-2f TCCGTCTTCCTATACCAGTCTG 
Cebpa-2r CACCCAGTCCCAGTGATAGT 
Cebpa-3f CTTCAAGCAGATCCCAGGAAC 
Cebpa-3r CTAGTTCCGACCCTTCCTCC 
Hsd11b1-1f ATGGGCATCCTACAATTTCCT 
Hsd11b1-1r GGTCAGAGAACATTGGGGAAC 
Hsd11b1-2f CCAACTGGCCAGAAAATTGC 
Hsd11b1-2r ATTGGCACCCTTTCCCCTAA 
Hsd11b1-3f GGCTCGTCCTTGGCTTAGA 
Hsd11b1-3r GCTGGTGGTGGAAGTGAAAG 
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